US20090062730A1 - Control of body fluid condition using diuretics, based on biological parameters - Google Patents

Control of body fluid condition using diuretics, based on biological parameters Download PDF

Info

Publication number
US20090062730A1
US20090062730A1 US12/202,094 US20209408A US2009062730A1 US 20090062730 A1 US20090062730 A1 US 20090062730A1 US 20209408 A US20209408 A US 20209408A US 2009062730 A1 US2009062730 A1 US 2009062730A1
Authority
US
United States
Prior art keywords
diuretic
infusion
pump
biological parameter
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/202,094
Inventor
San Hoon Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/202,094 priority Critical patent/US20090062730A1/en
Publication of US20090062730A1 publication Critical patent/US20090062730A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0496Urine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/05General characteristics of the apparatus combined with other kinds of therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3546Range
    • A61M2205/3569Range sublocal, e.g. between console and disposable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/16804Flow controllers
    • A61M5/16827Flow controllers controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths

Definitions

  • This invention relates to controlling body fluid condition using diuretics.
  • Body fluid imbalance is associated with many diseases such as congestive heart failure, liver cirrhosis and kidney disease.
  • Congestive heart failure in particular is a major cause of death and hospitalization.
  • mortality and hospitalization from congestive heart failure remains high.
  • causes of heart failure include coronary artery disease, hypertension, valvular heart disease, myocardial infarction, etc.
  • body fluid often increases and may lead to complications such as pulmonary edema.
  • Diuretics such as hydrochlorothiazide, furosemide and bumetanide are often used to treat this fluid accumulation by increasing the excretion of body fluid and sodium through the kidneys.
  • oral diuretics often fails to prevent heart failure exacerbation. This failure of diuretics to prevent heart failure can be explained by several mechanisms.
  • the dosage of oral diuretics prescribed by the doctor is often fixed, but the ideal dosage often changes depending on changing body conditions. For example, when people with heart disease eat salty food high in sodium content, their body fluid may increase significantly. We often see people come to the emergency room after they eat excessive amount of salt at a party. In this situation, people will require a higher dose of diuretics in order to excrete excessive body fluid and salt.
  • the required dose of diuretics is affected by the dietary intake of sodium, water and tendency to retain sodium. When body fluid builds up in the digestive system, it may cause intestinal edema (swelling). Bioavailability of diuretics may decrease with intestinal swelling. The body may not be able to absorb diuretics effectively. Patients may need to take higher dose of diuretics when poor bioavailability occurs.
  • sliding scale diuretic titration changes frequently, some patients may not understand the change of sliding scale diuretic titration and may end up taking the wrong dose of medication. This may lead to serious complications. Taking too much medication may lead to complications such as dehydration, electrolyte imbalance, hypotension, and kidney failure.
  • Conventional sliding scale diuretic titration is also limited to oral diuretics, which may not be as effective as, for example, continuous infusion of diuretics.
  • sliding scale diuretic titration when attempted, is typically based on a straightforward and simple protocol. More complex protocols generally have not been attempted because there is not a reliable way to carefully monitor and control the dispensing of diuretic or to adjust the dose according to varying conditions. In addition, there are not reliable safety measures to safeguard against the possible inappropriate use of diuretics. Without such controls and safety measures, more complex protocols can have a higher risk of inappropriate use of diuretics and possible adverse effects such as dehydration, electrolytes abnormalities, hypotension, and kidney failure.
  • One aspect of the present invention overcomes the limitations of the prior art by automatically infusing diuretic into a human patient.
  • the rate of infusion of the diuretic is adjusted based on various biological parameter(s) other than body weight, although possibly in combination with body weight.
  • the biological parameter(s) can be transmitted wirelessly to a portable diuretic infusion device attached to the patient, for example.
  • a portable diuretic infusion device in one aspect of the invention, includes a reservoir, a pump and a controller.
  • the reservoir can hold a diuretic or an antihypertensive drug to be infused into the patient.
  • the pump is connected to the reservoir and is also connectable to the patient, for example using an infusion set.
  • the pump is operated to infuse diuretic or other drug from the reservoir into the patient.
  • the controller controls the pump based on some biological parameter(s), thereby controlling the rate of infusion of the diuretic or other drug.
  • the controller adjusts the rate of infusion based on a measured intrathoracic electrical impedance of the patient.
  • the protocol may be designed to maintain a target intrathoracic electrical impedance for the patient, so that more diuretic is infused when the patient is over the target and less diuretic is infused when the patient is under the target.
  • the patient's intrathoracic electrical impedance can be measured by an implantable device and then wirelessly transmitted to the diuretic infusion device. The controller on the diuretic infusion device receives the intrathoracic electrical impedance information and automatically adjusts the infusion rate.
  • the diuretic infusion device adjusts the diuretic infusion rate based on various biological parameter(s).
  • biological parameters can include, for example, vital signs, blood pressure, intracardiac pressure, intravascular pressure, biomarker(s), physical sign(s), weight, NYHA classification, and/or symptoms,
  • the diuretic infusion system includes a biological parameter measurement apparatus with a biological parameter measurement sensor for measuring a biological parameter of a human patient and a wireless transmitter for wirelessly transmitting measured biological parameter information.
  • the diuretic infusion system also includes a portable diuretic infusion device with a reservoir for holding diuretic, a pump connected to the reservoir and connectable to the human patient, for infusing diuretic from the reservoir into the human patient, a wireless receiver for wirelessly receiving the biological parameter information transmitted by the biological parameter measurement apparatus, and a controller coupled to the wireless receiver, for controlling the pump and rate of infusion of the diuretic based on the received biological parameter information.
  • the diuretic infusion system is remote control operated.
  • the system can include a biological parameter measurement apparatus having a sensor for measuring a biological parameter of a human patient and a wireless transmitter for wirelessly transmitting biological parameter information based on the measured biological parameter.
  • the system can further include a portable diuretic infusion device with a reservoir for holding diuretic, a pump connected to the reservoir and connectable to the patient, a controller for controlling the pump, and a wireless receiver for wirelessly receiving commands.
  • the system can also include a remote control device with a wireless receiver for wirelessly receiving the biological parameter information transmitted, a wireless transmitter for wirelessly transmitting one or more commands to the portable diuretic infusion device, and a controller coupled to the receiver/transmitter for wirelessly controlling the pump and rate of infusion based on weight information.
  • a remote control device with a wireless receiver for wirelessly receiving the biological parameter information transmitted, a wireless transmitter for wirelessly transmitting one or more commands to the portable diuretic infusion device, and a controller coupled to the receiver/transmitter for wirelessly controlling the pump and rate of infusion based on weight information.
  • Other embodiments of the diuretic infusion system can include fewer or more components within the biological parameter measurement apparatus, the portable diuretic infusion device, and the remote control device.
  • the diuretic infusion system includes a urine output measurement apparatus with a urinary catheter, a urinary drainage apparatus, and a urine output sensor for measuring urine output of a human patient.
  • the urine output measurement apparatus also includes a wireless transmitter for wirelessly transmitting urine output information based on the measured urine output.
  • the system can also include a portable diuretic infusion device with a reservoir for holding diuretic, a pump connected to the reservoir and connectable to the patient for infusing diuretic from the reservoir into the patient, and a controller that controls the pump, thereby controlling a rate of infusion of the diuretic based on received urine output information.
  • the portable diuretic infusion device can include a wireless receiver for wirelessly receiving the urine output information transmitted from the urine output measurement apparatus.
  • the infusion system further includes a remote control device with a wireless receiver for wirelessly receiving the urine output information transmitted from the urine output measurement apparatus, and a wireless transmitter for wirelessly transmitting one or more command to the portable diuretic infusion device.
  • the remote control device can also include a controller coupled to the wireless receiver and transmitter for wirelessly controlling the pump and rate of infusion of the diuretic based on the received urine output information
  • the infusion rate can include both basal and bolus components.
  • Diuretic infusion can be supplemented and/or replaced by other delivery mechanisms, such as oral diuretics.
  • Fairly complex protocols can be implemented, since the protocol is more automated and depends much less on the patient implementing the protocol.
  • infusion rate can vary by time of day, thus reducing urination at nighttime.
  • Prospective infusion can also be implemented, for example if heavy salt intake is expected.
  • the infusion rate can also be adjusted based on feedback other than just weight.
  • FIGS. 1 depicts a diuretic infusion system.
  • FIG. 2 depicts a more detailed view of a diuretic infusion device.
  • FIG. 3 is a block diagram of a diuretic pump.
  • FIGS. 4 and 5 are a mechanical depiction of a diuretic pump.
  • FIG. 6 is a mechanical depiction of a diuretic pump with two reservoirs.
  • FIG. 7 shows data flow for computation of diuretic infusion rate.
  • FIG. 8 illustrates infusion of diuretic into the body.
  • FIG. 9 is a mechanical depiction of another diuretic pump.
  • FIGS. 10-11 further illustrate operation of further embodiments for diuretic dispensing.
  • FIG. 12 illustrates further embodiments for a diuretic infusion system.
  • FIG. 13 illustrates another diuretic infusion system.
  • FIGS. 14 and 15 show protocols for use with the diuretic infusion system of FIG. 13 .
  • FIG. 16 illustrates another diuretic infusion system including an electric scale.
  • FIGS. 17-20 show protocols for use with the diuretic infusion system of FIG. 16 .
  • FIG. 21-22 illustrates another diuretic infusion system including an implantable device.
  • FIG. 23 shows a protocol for use with the diuretic infusion system of FIG. 21 .
  • FIG. 24 illustrates another diuretic infusion system including a remote control device.
  • FIG. 25 illustrates a more detailed view of the diuretic infusion device and the remote control device.
  • FIG. 26 illustrates the operation of a closed loop drug infusion system for a diuretic infusion pump system.
  • FIG. 27 illustrates wireless communication of a diuretic infusion pump system with biological parameter measurement apparatuses.
  • FIG. 28 a diuretic infusion device with a patch sensor system.
  • FIG. 29 illustrate additional drug-infusion protocols
  • FIG. 30 illustrates a wirelessly-operated diuretic injecting pen-type device.
  • FIG. 31 illustrates the components of the diuretic injecting pen-type device.
  • FIG. 32 illustrates examples of the biological parameters measured by devices or sensor communicatively coupled to the diuretic injecting pen-type device.
  • FIG. 33 illustrates a data flow for computation of the diuretics dose for the diuretic injecting pen-type device.
  • FIG. 34 illustrates another type of drug-dispensing pen-type apparatus for dispensing pills.
  • FIG. 35 illustrates a disposable external diuretic infusion pump.
  • FIG. 36 shows another embodiment of a diuretic infusion pump with a feedback mechanism.
  • FIGS. 37 and 38 show various biological parameters and factors that may be used with various embodiments, such as that of FIG. 25 .
  • FIG. 39 illustrates a diuretic infusion system including a urine output measurement apparatus.
  • FIG. 40 illustrates the operation of the system of FIG. 39 .
  • FIG. 41 illustrates a wirelessly operated diuretic infusion system with urine output measurement apparatus.
  • FIG. 42 illustrates an example of a furosemide infusion protocol based on urine output.
  • FIG. 43 illustrates an ambulatory diuretic infusion pump with urine output measurement apparatus.
  • FIG. 44 illustrates another ambulatory diuretic infusion pump.
  • FIG. 1 depicts a diuretic infusion system according to the invention.
  • Diuretic infusion device 101 is located on the patient's body 102 .
  • Weight sensor 103 measures the patient's body weight. In one embodiment, the weight sensor 103 is an electric scale.
  • a user inputs measured body weight into the diuretic infusion device 101 .
  • the diuretic infusion device 101 delivers diuretic to the human body 102 .
  • the dose of the diuretic is determined based on the measured body weight.
  • Various diuretics may be used with the diuretics infusion device. Examples include hydrochlorothiazide, chlorothiazide, chlorthalidone, metolazone, furosemide, bumetanide, ethacrynic acid, torsemide, spironolactone, indapamide and eplerenone.
  • Vasopressin receptor antagonist may also be used. Examples include conivaptan, tolvaptan. Brain natriuretic peptide may also be used. One example is nesiritide.
  • FIG. 2 is a close-up of the diuretic infusion device 101 of FIG. 1 .
  • the diuretic infusion device 101 is a diuretic pump 201 that is attached to the body 207 .
  • a preferred location is around the body waist and abdomen.
  • the size of the diuretic infusion pump can vary. In one implementation, the diuretic pump is 2.2 ⁇ 3.7 ⁇ 1 inches.
  • This diuretic infusion pump 201 includes a wireless communications chip, processing module, batteries and processor (see FIG. 3 for further detail).
  • the diuretic infusion pump 201 may not include the wireless communications chip in alternative embodiments.
  • An external keypad to allow the user to program an onboard processor.
  • the onboard processor controls the rate of diuretic infusion.
  • Various buttons 202 , 203 are used for various functions, such as programming the diuretics pump and adjusting the diuretic infusion rate.
  • Information such as rate of diuretic infusion, name of diuretics in use, weight information, and optimal or target weight, can be displayed on the screen 204 .
  • This screen also shows signals that indicate malfunction of the device and other signals such as time to change a diuretics cartridge or time to change a battery.
  • This diuretic infusion pump 201 includes a disposable reservoir or a disposable cartridge for the diuretic.
  • the prefilled cartridge containing diuretics is replaced when empty.
  • the reservoir and/or cartridge may not be disposable. Instead, the reservoir may be refilled when empty.
  • a disposable infusion set for the diuretic infusion pump may include a cannula 209 , an adhesive pad 205 , a needle 208 and tubing system 206 (that delivers the diuretic reservoir to a user).
  • the user inserts the needle 208 together with the cannula 209 under the skin.
  • the needle 208 may be removed, leaving the cannula 209 under the skin.
  • the tip of the cannula 209 is located at the subcutaneous tissue.
  • the tip of cannula 209 may be located in the abdominal cavity, intramuscular space, intravascular space or peritoneal cavity.
  • the cannula 209 may be made with biocompatible materials such as polyethylene.
  • FIG. 3 is a block diagram of a diuretic pump.
  • Processor 301 (the controller) is contained in the interior of the housing 316 of the diuretic infusion pump.
  • the housing 316 may be made of plastic or steel, for example.
  • Processor 301 runs software programs and controls components of the diuretics infusion pump.
  • the Freescale Dragonball microprocessor is one example of a processor that may be used.
  • the Motorola 6805 is another example.
  • the Freescale MC9S08RX32A is another example.
  • the MC9S08RX32A includes an RF integrated circuit and microcontrollers (MCU). Other processors that are used in insulin pumps may also be used.
  • MCU microcontrollers
  • the processor 301 is in electrical communication with an electric motor and pump 313 .
  • the processor controls the electric motor 313 according to its program.
  • the processor also controls a screen 304 , an audible alarm 307 , vibratory alarm 308 and telemetry system.
  • Weight information that is transmitted from the weight measurement apparatus is received by the telemetry system of the diuretic infusion pump. It then enters the processor 301 .
  • weight information may be input into the diuretic infusion pump manually by a user, for example from a keypad or a remote controller.
  • flash memory 314 and SRAM 315 are used for memory storage.
  • This memory may store information such as pump settings, a historical log of weight, malfunctions of the pump, infusion rate, a historical log of infusion rate, medication, etc.
  • the RAM has 100 kilobytes
  • ROM has 4 megabytes
  • flash memory has 4 megabytes memory.
  • Alternate memory media include RAM, ROM, EPROM, DRAM, hard-drives and other types of flash memory.
  • the user may program the processor 301 using a keypad (or other user interface) on the diuretic infusion pump.
  • a user may use a remote controller or a computer station to program the processor 301 .
  • Wireless technologies include radio frequency (RF), infrared (IR) and optical.
  • Specific technologies include Bluetooth, DECT, ZigBee, NFC, GSM, UWB, UMTS, DAB, CDMA, WiFi and WIMAX.
  • Wired communications ports can include Universal Serial Bus (USB) ports and/or RS-232 ports, as well as other technologies.
  • the diuretic infusion pump displays on its screen whether new weight information, command, or alerts are received.
  • the diuretic infusion pump, weight measurement apparatus, corresponding computer systems and/or remote controller may be assigned a unique identifier and/or password to provide privacy for its users.
  • a keypad 309 is located on the housing 316 .
  • a touch screen input device may also be used.
  • the keypad 309 shown in FIG. 2 includes buttons 203 , 202 to provide input to the processor 301 .
  • Various other inputs may also be included in the diuretic infusion pump (or communicate to the diuretic pump from other parts of the system).
  • motion detection sensor 312 may be used to detect the motion of a gear in the drive mechanism for the pump.
  • Cartridge sensor or reservoir sensor 311 may be used to detect the amount of diuretic left within a cartridge or reservoir, and to notify a user when a new cartridge is required or a reservoir requires refilling.
  • LCD is used as a screen. Feedback from the weight measurement apparatus, a computer, a remote control device as well as diuretic infusion pump status and programming changes may be displayed on a LCD screen. Time, name of drug, dose of drug used during a particular period of time, reservoir or cartridge usage and history may also be displayed.
  • a speaker can be used to send audio feedback.
  • a user may choose to use a vibratory alarm instead of audible alarm. For example, if measured body weight is too low or too high, an audible or vibratory alarm may warn a user. If measured body weight is lower than a set value, a certain instruction such as “Drink more water and eat more because you may be dehydrated” may be shown on the screen or played through the speaker.
  • Alarms may also be activated for pump malfunction, low battery, dead battery, occlusion of infusion set, near-empty cartridge (or reservoir), pump delivery error, if bolus is changed, if mode is changed, if pump is not primed, if infusion exceeds maximum limits, etc.
  • the diuretic infusion pump preferably uses a AAA alkaline battery. More than one AAA alkaline batteries may be used. Alternatively, different types of batteries may be used such as nickel cadmium battery, nickel metal hydride battery, lithium ion battery, carbon battery, lithium battery and 3.6V lithium battery. The battery may be included inside the housing 316 of the diuretic infusion pump.
  • FIG. 4-5 are mechanical depictions of a diuretic pump.
  • the diuretic infusion pump contains a processor 401 .
  • the processor is electrically connected or otherwise communicatively coupled to an electric motor 402 , for example a DC motor with gear-reducer.
  • the processor 401 controls the electric motor 402 according to its programming.
  • the electric motor 402 is connected to a peristaltic pump 404 .
  • the peristaltic pump 404 has a rotor inside.
  • a flexible tube inside the peristaltic pump 404 is connected with a tube 405 and 408 .
  • the flexible tube is in contact with the rollers. When the rotor turns, one or more rollers squeeze and release the flexible tube to deliver drug from a reservoir 403 to a user via the infusion tube 408 .
  • FIG. 5 is a simplified mechanical depiction of a syringe pump system.
  • the pump housing 515 contains a syringe 516 .
  • the syringe 516 contains diuretics.
  • the processor 510 is electrically connected or otherwise communicatively coupled to an electric motor 511 .
  • the processor 510 controls the electric motor 511 according to its programming.
  • the motor 511 rotates a motor gear which moves a screw 513 axially.
  • a screw 513 is configured to move axially to push a plunger 514 inside a syringe and push diuretics out of a syringe 516 or a reservoir through an infusion tube 518 and a cannula 519 .
  • the plunger mechanism transfers the diuretics solution from a diuretics cartridge or reservoir through an outlet of the housing to the patient via tubing system 405 , 408 and the infusion set. Technologies used in insulin pumps may be used also for diuretic pumps.
  • more than one type of drug may be used in the diuretic infusion pump.
  • a processor may be coupled with more than one program, software, protocols and/or parameters that are tailored according to the specific drug that is used.
  • the diuretic infusion pump may automatically recognize the inserted drug.
  • Drug reservoir or cartridge may have a unique identification code.
  • One example of a drug name recognition method is to decode the bar code of the drug name, which is attached on the reservoir or cartridge.
  • the name of the inserted drug may be manually put into the diuretic infusion pump using the keypad which can select alphabets on the screen.
  • Examples of medications that may be contained in the reservoir 807 or cartridge include hydrochlorothiazide, chlorothiazide, chlorthalidone, metolazone, furosemide, bumetanide, ethacrynic acid, torsemide, spironolactone, eplerenone, vasopressin receptor antagonists, conivaptan, tolvaptan, brain natriuretic peptide, and nesiritide.
  • FIG. 6 is a mechanical depiction of a diuretic pump with two reservoirs: in this case a diuretics reservoir 601 and an insulin reservoir 602 .
  • Patients with diabetes may also have congestive heart failure.
  • This device delivers both diuretics and insulin using one ambulatory infusion pump.
  • each medication is delivered via tubes 603 , 604 inside an ambulatory infusion pump and leaves the housing of the pump via a tube 609 outside the ambulatory infusion pump. There may be two separate channels within the tube 609 through which each medication is delivered separately. Each medication is delivered to a user through different holes 611 , 612 .
  • a syringe pump system can be used instead of a peristaltic pump 606 . Two syringes can have separate electric motors that control the movement of the plunger of the respective syringes and release of each medication.
  • a processor 610 controls an electric motor 605 and a pump 606 according to its program. More than two electric motors and pumps may be used in alternative embodiments. A separate electric motor and pump may be used to deliver different medications in alternative embodiments.
  • FIG. 7 shows possible data flow for computation of the diuretic infusion rate.
  • the processor of the diuretic infusion pump uses weight to compute the diuretics infusion rate.
  • the processor may use various other factors to compute diuretic infusion rate. Examples include physical signs, vital signs, bio markers, symptoms, intracardiac pressure, intravascular pressure, intrathoracic electrical impedance and New York Heart Association (NYHA) classification, as shown in FIG. 7 . For example, if BNP (B-type natriuretic peptide) is elevated, this may indicate increased body fluid volume and congestive heart failure. If BNP is above 100 pg/ml, the diuretic infusion pump may increase (or adjust) the infusion rate until the levels returns to normal.
  • BNP B-type natriuretic peptide
  • ANP Atrial natriuretic peptide
  • CNP C-type natriuretic peptides
  • NT-pro BNP NT-pro BNP
  • ventricular natriuretic peptides and other bio markers that indicate volume overload and heart failure may also be used to compute the diuretic infusion rate.
  • Physical signs of volume overload such as ankle swelling, leg swelling, arm swelling, and abdominal distension can also be used.
  • a user may use a scale of one to four in body swelling as one being no swelling, four being severe swelling, three being moderate swelling, two being mild swelling.
  • the diuretic infusion pump might adjust the infusion rate to return body swelling to the zero score condition of no swelling.
  • the diuretic infusion pump may also adjust the infusion rate based on blood pressure.
  • the diuretic infusion pump may also adjust the infusion rate by using symptom scores such as a shortness of breath scale (one to four, one-no difficulty breathing, two-mild difficulty, three-moderate difficulty, four-severe difficulty) or a walking scale (one- can walk without limitations, two-can walk less than one block, three-can barely walk even inside home).
  • symptom scores such as a shortness of breath scale (one to four, one-no difficulty breathing, two-mild difficulty, three-moderate difficulty, four-severe difficulty) or a walking scale (one- can walk without limitations, two-can walk less than one block, three-can barely walk even inside home).
  • the diuretic infusion pump may use the NYHA (New York Heart Association) classification to compute the diuretics infusion rate.
  • NYHA New York Heart Association
  • the NYHA classification is widely used to assess the stage of heart failure.
  • the diuretic infusion pump may adjust diuretics infusion rate to improve patient condition from class II, III or IV to class I.
  • Combinations of variables may be used for the computation of diuretic infusion rate and/or dose. These variable(s) may be used for the computation of the dose and/or infusion of other drugs. Some examples of these drugs include, but not limited to, anti-hypertensive drug, inotropic agents, and anti-arrhythmic drugs.
  • Adjusting the diuretic dose according to intracardiac pressure or central vein pressure is another possibility.
  • FIG. 8 illustrates infusion of diuretic into the body.
  • diuretic medication is infused into subcutaneous tissue.
  • diuretic medication may be infused into a peritoneal cavity, an intravascular space (e.g., into a vein) or intramuscularly.
  • the diuretic infusion pump 807 attaches to a tubing system 806 , an adhesive 805 and a needle 803 .
  • a plastic tube 801 (a catheter) is attached to a silicone bubble 804 (septum). Tip 808 of the plastic tube may be located into a peritoneal space or a vein (or an artery). A needle 803 is inserted into the silicone bubble. Medication is delivered from the infusion pump 807 through a tubing system 808 , a needle 803 and a plastic tube 801 into a target space of a user. Examples of a target space include a peritoneal space, a vein, an artery and a muscle.
  • a port 802 and silicone bubble 804 may be located in subcutaneous tissue or may be located outside the skin.
  • FIG. 9 is a mechanical depiction of yet another diuretic pump. More than two drugs may be infused in alternative embodiments. Two drugs are contained in the separate drug reservoir or cartridge. One example of two drugs that may be used includes diuretics and insulin. Another example of two drugs that may be infused includes loop diuretics and thiazide diuretics.
  • loop diuretics and vasopressin receptor antagonist examples include “loop diuretics and vasopressin receptor antagonist”, “thiazide diuretics and vasopressin receptor antagonist”, “loop diuretics and potassium sparing diuretics”, “thiazide diuretics and potassium sparing diuretics” and “loop diuretics and carbonic anhydrase inhibitor.”
  • Loop diuretics act on the ascending loop of Henle in the kidney.
  • Thiazide diuretics act on distal convoluted tubule in the kidney.
  • vasopressin receptor antagonists examples include conivaptan and tolvaptan.
  • FIG. 6 shows an infusion pump with two drug reservoirs 601 , 602 that share one pump 606 .
  • FIG. 9 shows two peristaltic pumps 903 , 904 connecting with two different reservoirs 901 , 902 .
  • a processor 905 is electrically connected with electric motors 911 , 912 .
  • the processor 905 controls these electric motors 911 , 912 and pumps 903 , 904 to deliver medication from each medication reservoir 901 , 902 .
  • the pump 903 is connected with a reservoir 901 and delivers a medication from a reservoir 901 through a tubing system 906 , 908 to a user.
  • the pump 904 is connected with the reservoir 902 and delivers medication from the reservoir 902 through a tubing system 907 , 909 to a user.
  • the tube 908 merges with tube 909 .
  • there are different channels within the tube to deliver each medication through different channels to prevent mixture of non-compatible medications.
  • These two medications are delivered through separate openings 910 , 913 .
  • Two medications may be delivered according to two separate programs, protocols, parameters.
  • a diuretic inhaler may be used. Examples include a furosemide inhaler, a bumetanide inhaler, and so forth. If measured body weight is above a previously set target weight, the display on the weight measurement apparatus, the diuretic inhaler or a separate device may show instructions on the dose of drug to be inhaled. For example, if measured body weight is one kilogram above the target weight, a user may be instructed to have one extra-inhalation of furosemide.
  • Other diuretic inhalers including (but not limited to) furosemide, bumetanide, and torsemide, may be used in alternative embodiments.
  • FIGS. 10 further illustrate operation of other embodiments.
  • the diuretic infusion device has various other functions that may improve the health of patients. For example, if intravascular pressure increases due to increased body fluid, it helps to remind patients to control the amount of salt (sodium) that they take daily.
  • the display 1002 shows instructions to avoid food high in sodium chloride.
  • This device may also provide a list of foods high in sodium content, low in sodium content, high in potassium, magnesium, calcium, and/or low in potassium, magnesium, calcium. Diet information may be provided for educational purposes.
  • the device may have a scanner to scan food to notify users whether scanned foods are appropriate for users to take or not.
  • the data e.g.
  • the food scanning can be performed by a separate device such as PDA, a handheld computer, a remote control device, a portable phone, an iPHONETM, an iPODTM, and so forth.
  • the diuretic infusion device may also be connected with a blood pressure cuff, either wirelessly or in a wired manner. Blood pressure information measured by the blood pressure cuff is transmitted to the diuretic infusion pump. Certain instructions may be provided on the display 1002 . See FIG. 16 . A database of references on health topics, drug information, emergency instruction, BLS (basic life support) may be saved in the memory within diuretic infusion device or diuretic dose instruction device and can be viewed on the display of the device. Examples of instructions include reminding a user to take antihypertensive medications as scheduled, instructing a user to adjust the dose of antihypertensive medications if blood pressure is low or high.
  • a user may be instructed to call his doctor or go to the nearby emergency room or call 911.
  • a user may press an emergency button 1003 to notify family, help agent, 911 or hospital for help during emergent situations.
  • FIGS. 12 and 14 show additional protocols for diuretic dispensing.
  • FIG. 11 illustrates another example.
  • Diuretic infusion pump 1101 has a screen 1 102 .
  • a user uses a keypad to edit target intravascular pressure information.
  • the target intravascular pressure is displayed on the screen.
  • a cursor is located on the number of the intravascular pressure. In this FIG. 11 , it is located on the digit 12 1103 .
  • a user can choose different number using scrolls 1104 , 1105 .
  • S button 1106 is pressed to select a number.
  • the current intravascular pressure can be manually put into the diuretic infusion pump in a similar manner.
  • a furosemide infusion protocol is shown on the screen 1201 of the diuretic infusion pump 1202 .
  • the underlined numbers can be changed using scroll buttons 1203 , 1204 . If scroll button 1203 is pressed, the number increases. If scroll button 1204 is pressed, the number decreases. The cursor is located on underlined thick number 1207 , which is a 8. If scroll button 1203 is pressed once, the 8 changes to 9. If scroll button 1204 is pressed once, the 8 changes to 7. If button S 1205 is pressed, the number is selected. If button S is pressed when number 1207 is 8, the 8 is selected and cursor moves on to next underlined number 1208 . If all numbers are selected, button M is pressed to move on to another menu.
  • FIG. 13 illustrates another diuretic infusion system.
  • An implant 1304 is located under the skin of human body 1301 .
  • the tip of the wire of the implant is located inside a cardiac chamber 1302 to monitor intracardiac pressure.
  • the tip of the wire of the implant may be located in a central vein, pulmonary artery or other vessel in alternative embodiments.
  • a pressure measuring sensor is attached to the tip or other portion of the wire of the implant.
  • the implant may be coupled with a processor, wireless communication module, a controller and a software program.
  • the diuretic infusion pump 1303 communicates wirelessly with the implant 1304 that monitors intracardiac pressure and/or central vein pressure. If the pressure is elevated inside the cardiac chamber or central vein, this may indicate a sign of volume overload.
  • the diuretic infusion pump may adjust its infusion rate according to the pressure measured by this implant.
  • a user inputs a target pressure into the diuretic infusion pump.
  • the diuretic infusion pump adjusts its infusion rate to maintain the target pressure.
  • a suitable implant is the Chronicle heart monitor made by MEDTRONICTM.
  • a pacemaker, an automatic implantable cardioverter defibrillator (AICD), or a cardiac resynchronization therapy (CRT) device may be coupled with the pressure measuring sensor, wireless communication module, processor and software program to transmit pressure signals to the diuretic infusion pump.
  • AICD automatic implantable cardioverter defibrillator
  • CRT cardiac resynchronization therapy
  • FIG. 14 illustrates a diuretics protocol that may be used with the diuretic infusion device of FIG. 13 .
  • a pressure monitoring sensor is located in the central vein, for example the superior vena cava.
  • the implant shown in FIG. 13 transmits a pressure signal wirelessly to the diuretic infusion pump.
  • the diuretic infusion pump adjusts the diuretic infusion rate according to the pressure measured by the pressure monitoring sensor, as shown in FIG. 14 .
  • the diuretic infusion pump adjusts the infusion rate to maintain a target pressure within the cardiac chamber, central vein or other vessel.
  • Various other protocols may be used to adjust diuretic infusion according to the pressure.
  • the pressure signal can also be used to trigger safety measures.
  • the diuretic infusion device can be programmed to automatically stop infusion and notify a user if the blood pressure falls below a previously set value. This is to avoid hypotension that may occur with use of high dose diuretics.
  • a diuretic infusion pump may be programmed to automatically stop infusion and notify the user (and/or doctor), if the systolic blood pressure is below 90 mmHg.
  • Various non-invasive biological parameter measurement device such as a patch sensor system, a non-invasive central aortic pressure measurement device, a non-invasive intravascular blood pressure measurement device may be coupled with a diuretic infusion pump wirelessly or via other means such as manual data input and wired communication.
  • FIG. 15 shows another example of furosemide protocol.
  • a blood pressure monitoring sensor located in a central vein can transmit a measured blood pressure signal to the diuretic infusion pump.
  • the diuretic infusion pump displays the instructions regarding the dosage of oral furosemide.
  • FIG. 16 depicts another embodiment of the present invention.
  • a blood pressure cuff 1604 is attached to an arm of a human body 1602 .
  • the blood pressure cuff 1604 can be connected to a blood pressure measuring device 1605 .
  • the blood pressure measuring device 1605 can be coupled to a processor, wireless communication module, a controller and a software program, though it may not be coupled to all of these in some embodiments.
  • the diuretic infusion pump 1601 can communicate wirelessly or via other means with the blood pressure measuring device 1605 .
  • the blood pressure measuring device 1605 can communicate wirelessly or via other means with an electric scale 1603 .
  • a user manually inputs measured blood pressure into a diuretic infusion device or a remote control device.
  • FIG. 17 illustrates another example of a furosemide infusion protocol.
  • the diuretic infusion pump receives the measured blood pressure wirelessly from the blood pressure measurement device. If the measured blood pressure is below a set blood pressure, the diuretic infusion pump can be programmed to stop furosemide infusion automatically to prevent hypotension, dehydration.
  • FIG. 18 illustrates an example of a furosemide and enalaprilat infusion protocol.
  • the diuretic infusion pump can contain more than one drug reservoir.
  • the diuretic infusion pump has one reservoir containing furosemide and another reservoir containing enalaprilat.
  • Enalaprilat is an angiotensin converting enzyme (ACE) inhibitor which is an antihypertensive drug.
  • ACE angiotensin converting enzyme
  • the protocol in FIG. 45 shows the diuretic infusion pump infusing enalaprilat as well as furosemide according to measured blood pressure to maintain target blood pressure.
  • FIG. 19 illustrates another example of a furosemide and enalaprilat infusion protocol.
  • the diuretic infusion pump adjusts the infusion rate and a dose of enalaprilat and furosemide according to the measured blood pressure to maintain target blood pressure.
  • FIG. 20 illustrates an example of furosemide and metoprolol infusion protocol.
  • Metoprolol is a beta blocker which lowers blood pressure and heart rate.
  • the diuretic infusion pump may contain one reservoir containing furosemide and one reservoir containing metoprolol.
  • the diuretic infusion pump adjusts the infusion rate and dose of metoprolol and furosemide according to the measured blood pressure to maintain target blood pressure.
  • the diuretic infusion pump may adjust the infusion rate and dose of metoprolol to maintain target heart rate.
  • a patient with heart disease may develop arrhythmia, such as supraventricular tachycardia (rapid heart rate), atrial fibrillation, or ventricular tachycardia.
  • the diuretic infusion pump can infuse metoprolol to lower heart rate.
  • the diuretic infusion pump can communicate wirelessly with an implantable cardioverter defibrillator (ICD), a pacemaker. If an ICD or a pacemaker detects arrhythmia, the ICD or pacemaker can send this arrhythmia information wirelessly or via other means to the diuretic infusion pump.
  • the diuretic infusion pump may infuse an anti-arrhythmic drug to treat the arrhythmia.
  • anti-arrhythmic drugs include, but are not limited to, amiodarone, metoprolol, sotalol, esmolol, lidocaine, disopyramide, propafenone, dofetilide, flecainide, procainamide and atropine.
  • the diuretic infusion pump may contain and infuse only anti-arrhythmic drug communicating with an ICD or a pacemaker in alternative embodiments.
  • a user can use one reservoir that contains diuretics and a second reservoir that contains an inotropic drug that increases blood pressure.
  • inotropic drugs include (but are not limited to) dopamine, dobutamine, phosphodiesterase inhibitor, amrinone, milrinone, enoximone, pimobendan, levosimendan, calcium sensitizing agent, venarinone, and ibopamine.
  • the diuretic infusion pump contains a combination of antihypertensive drugs, inotropic agents, diuretics, and it adjusts the infusion rate according to blood pressure measured by non-invasive blood pressure measurement device and/or measured body weight.
  • FIG. 21 depicts another embodiment.
  • An implantable device 2104 has a pair of electrodes on the surface.
  • the implantable device 2104 is connected to a cardiac ring electrode or coil electrode positioned in the heart 2105 in the human body 2101 via a wire 2102 .
  • Intrathoracic impedance between the implantable device case and the right ventricular lead can be measured multiple times a day. If the intrathoracic impedance decreases, this may suggest fluid is accumulating in the lungs due to worsening heart failure.
  • the implantable device 2104 can be a pacemaker, an implantable cardioverter defibrillator, or a cardiac resynchronization therapy device.
  • One example of a suitable implant is OptiVol fluid status monitoring device from Medtronic.
  • the diuretic infusion pump 2103 can communicate wirelessly with the implantable device 2104 .
  • the diuretic infusion pump 2103 can adjust the infusion rate of diuretics according to the measured impedance to maintain the target impedance.
  • FIG. 49 illustrates an example of a furosemide infusion protocol according to measured intrathoracic impedance.
  • the diuretic infusion pump may adjust the infusion rate of diuretics according to the average of impedance measurements taken over a predetermined period of time to maintain target measured average impedance.
  • FIG. 22 depicts another embodiment.
  • the diuretic infusion pump 2203 receives weight information wirelessly or manually from a weight measurement device 2201 and communicates wirelessly with the implantable device 2204 which was shown in FIG. 21 .
  • FIG. 23 illustrates an example of a furosemide infusion protocol according to measured intrathoracic impedance.
  • the diuretic infusion pump may adjust the infusion rate of diuretics according to the average of impedance measurements taken over a predetermined period of time to maintain target measured average impedance.
  • FIG. 24 illustrates another embodiment.
  • a diuretic infusion device 2401 is attached to a human body 2402 .
  • This portable diuretic infusion device 2401 delivers diuretics from a reservoir to the human body 2402 .
  • the diuretic infusion device 2401 may be smaller in size compared to other embodiments shown in other figures.
  • This diuretic infusion device 2401 can be disposable.
  • the diuretic infusion device 2401 contains a reservoir, a programmable processor, an exit port, a cannula and a motor, though some embodiments may contain fewer components or additional components.
  • the diuretic infusion device 2401 can communicate wirelessly or via other means with a remote control device 2404 .
  • the remote control device 2404 can communicate wirelessly with an intrathoracic impedance measurement device 2405 and a diuretic infusion device 2401 in one embodiment.
  • the remote control device 2404 may communicate wirelessly with only the diuretic infusion device 2401 , and not with the intrathoracic impedance measurement device 2405 in alternative embodiments.
  • FIG. 25 further illustrates the diuretic infusion device 5101 .
  • the diuretic infusion device 2501 has a needle 2503 and cannula 2502 .
  • the diuretic infusion device 2501 is connected to a human body 2511 subcutaneously via a cannula 2502 .
  • the diuretic infusion device 2501 is disposable in some embodiments, but the reservoir of the diuretic infusion device can alternatively be refilled via a hole 2505 .
  • the remote control device 2504 programs and controls the diuretic infusion device 2501 .
  • the remote control device 2504 contains a programmable processor, a controller, a wireless transmitter/receiver, a keypad with order entry buttons 2507 , 2508 , 2509 , 2510 and a display screen 2506 , though some embodiments may contain fewer components or additional components. Measured biological parameters shown in other figures can be transmitted wirelessly from a biological parameter measurement device to the remote control device 2404 , 2504 in this embodiment. In alternative embodiments, a user manually inputs measured biological parameters into the remote control device 2504 .
  • a controller of the remote control device 2504 may be coupled to a processor and a wireless receiver/transmitter. When biological parameter information enters the processor of the remote control device 5104 , the processor can compute the dosage of diuretic based on the biological parameter(s).
  • the remote control device 2504 wirelessly transmits commands to the diuretic infusion device 2501 .
  • the remote control device 2504 can control the infusion rate of the diuretic infusion device 2501 wirelessly or by other means (e.g., wired).
  • a user can choose and program particular diuretic infusion protocol(s) using button(s) 2507 , 2508 , 2509 , 2510 on the keypad of the remote control device 2504 .
  • Various drug infusion protocols and methods shown in other figures may be embedded in the processor of the remote control device 2504 .
  • the processor within the remote control device 2504 may be able to compute the dosage of a diuretic based on the amount of salt, sodium and/or water of food. A user may infuse a diuretic before or when the user eats food that contains salt and/or water to excrete extra salt and water to maintain optimal body fluid condition. In other embodiments, the processor within the remote control device 2504 computes the dosage of diuretic based on various biological parameters using protocols shown in other figures. For example, FIGS. 36 and 37 show various biological parameters and factors that may be used in these embodiments.
  • the biological parameter measurement sensors can be coupled with an implantable device(s) like a pacemaker, an implantable cardioverter defibrillator, a cardiac resynchronization therapy, etc.
  • the remote control device 2504 can communicate wirelessly with the biological parameter measurement sensor(s).
  • An intracardiac/intravascular pressure monitoring sensor, an intrathoracic impedance monitor sensor, or a patch sensor can communicate wirelessly with the remote control device 2504 in alternative embodiments.
  • FIG. 26 illustrates another embodiment of the present invention.
  • the diuretic infusion pump system can be a closed loop drug infusion system.
  • the closed loop drug infusion system includes a biological parameter measurement sensor and/or a biological parameter measurement device, a controller, drug infusion pump, a drug delivery system, wireless communication module, though not all of these may be included in alternative embodiments or additional modules or devices may be included.
  • measured biological parameter signal enters the controller of the diuretic infusion system wirelessly or via other means.
  • the controller of the diuretic infusion pump automatically adjusts and controls the drug infusion according to the algorithms programmed in the diuretic infusion pump in the closed loop drug infusion system.
  • the controller of the diuretic infusion pump adjusts the drug infusion to achieve or maintain a target biological parameter which is programmed into the diuretic infusion pump.
  • biological parameter measurement sensors and/or biological parameter measurement devices can be used for the present invention.
  • these biological parameter measurement sensors/devices include, but are not limited to, a patch sensor system, an intracardiac pressure sensor system, an intravascular pressure sensor system, an intrathoracic impedance monitor sensor system, a non-invasive blood pressure measurement sensor system, a weight measurement sensor and/or device, a blood pressure measurement cuff and device, a heart rate measurement sensor system, an electrocardiogram monitoring sensor and/or device, an arrhythmia monitoring sensor system and other vital sign measurement devices.
  • These biologic sensors can be coupled with other implantable medical devices, such as a pacemaker, an ICD, or a cardiac resynchronization therapy.
  • the biological parameter measurement sensor/device and the diuretic infusion pump can preferably communicate wirelessly.
  • the sensor/device and the diuretic infusion pump may communicate via other means in alternative embodiments.
  • Other means may include, but are not limited to, wired communication, manual data input and other methods described in the present invention.
  • More than one biological parameter sensor and/or device may be used in combination with a diuretic infusion pump.
  • a weight measurement device and intravascular blood pressure measurement sensor system may be used in combination with a diuretic infusion pump.
  • a weight measurement device and a patch sensor may be used in combination with a diuretic infusion pump.
  • These different sensors and devices may communicate wirelessly or via other means.
  • Different types of patch sensors may be included in the closed and/or open loop drug infusion system.
  • the patch sensor is further described in FIG. 28 .
  • the drug infusion system may adjust the infusion of drug(s) according to an average (e.g., a mean or median) value of biological parameters in alternative embodiments.
  • the drug infusion system can adjust the infusion of diuretics according to the average of the measured weight over three days. If the daily measured body weight is 70 kg, 72 kg, 71 kg over the past three days, the diuretic infusion pump can be programmed to adjust the rate of diuretic infusion according to 71 kg which is median value of three measured weights.
  • the drug infusion system can adjust the infusion of diuretics according to the average value of measured intrathoracic electrical impedance over a period of time.
  • the diuretic infusion pump is programmed to adjust the rate of diuretic infusion according to an average value of biomarkers, blood pressure, intracardiac pressure or other biological parameters mentioned previously over a certain period of time.
  • the diuretic infusion pump system is an open loop drug infusion system.
  • the diuretic infusion pump can receive measured weight or other biological parameters from sensor(s) wirelessly or manually, however the diuretic infusion pump may or may not automatically adjust the rate of infusion in an open loop system.
  • a user, a doctor, a nurse and/or other people that are involved in the use of the diuretic infusion pump system may need to approve or choose particular protocol(s) and methods. These people can also control the controller of the diuretic infusion pump.
  • Healthcare provider(s) can transmit a new order or new drug infusion protocols to the diuretic infusion pump system via the Internet, a phone, or other methods.
  • wireless communication among the devices may or may not be used.
  • a user chooses an open loop system, a closed loop system, or mixed loop system (e.g., a closed loop system when a certain conditions are met and open loop system when a certain conditions are not met).
  • the diuretic infusion pump system can be programmed to be a closed loop system when measured blood pressure is within a certain parameter, when a user does not have symptoms, such as chest pain, and/or when the dosage of an infused drug is within a certain range.
  • the diuretic infusion pump can be programmed to be an open loop system when these conditions are not met in a mixed loop system.
  • FIG. 28 illustrates a patch sensor system 2802 and a drug infusion pump 2803 .
  • the patch sensor system 2802 is attached to a human body 2801 .
  • the patch sensor system can contain more than one sensor 2804 , 2805 and/or electrodes 2804 , 2805 .
  • the patch sensor system can be coupled to a processor, wireless communication module, a controller and software program, though it may not be coupled to all of these in alternative embodiments or may be coupled to additional devices.
  • the patch sensor system 2802 measures blood pressure, heart rate, intrathoracic electrical impedance, body fluid status, heart rhythm, biomarkers, and detects heart arrhythmia.
  • This patch sensor 2802 is preferably attached to the chest, but may be attached to back, head or other parts of the body in alternative embodiments.
  • the patch sensor 2802 can include an electrode generating an electrical waveform and/or an optical system generating an optical waveform to measure various biological parameters, such as blood pressure, pulse, oxygen saturation, heart rhythm.
  • Intrathoracic electrical impedance can be measured by the patch sensor system 2802 using multiple electrodes and/or multiple sensors. Intrathoracic impedance between multiple sensors and electrodes can be measured multiple times a day in one embodiment.
  • the patch sensor system 2802 communicates wirelessly with the diuretic infusion pump 2803 in a closed loop drug infusion system or an open loop drug infusion system.
  • the diuretic infusion pump 2803 adjusts the infusion of diuretics and/or other drugs according to biological parameter(s) measured by the patch sensor system 2802 to maintain the target biological parameter.
  • the diuretic infusion pump can adjust the infusion of diuretics and/or other drug(s) to maintain, for example, target blood pressure, intrathoracic impedance, heart rate, body fluid condition surrogate marker, etc., using drug infusion protocols shown in other figures.
  • More than one patch sensor system 2802 can be used and attached to different parts of the body.
  • One example of a suitable external patch sensor monitoring system is MUSETM clinical system from CORVENTISTM, INC.
  • FIG. 29 illustrates another example of a drug infusion protocol.
  • the measured intracardiac pressure of a user is 17 mmHg and the target intracardiac pressure is set at 12 mmHg. There is 5 mmHg difference between the target cardiac pressure and measured cardiac pressure, and the measured cardiac pressure is above the target cardiac pressure.
  • the basal rate of furosemide infusion increases by 0.3 mg multiplied by 5 and 0.3 mg multiplied by 5 is equal to 1.5 mg.
  • the basal rate of furosemide infusion increases by 1.5 mg per hour for 8 hours following the protocol.
  • the new basal rate of the furosemide is 2.5 mg per hour for 8 hours daily.
  • a user or a healthcare provider can change the underlined numbers according to a person's sensitivity to diuretics. The change of the protocol could occur automatically or occur upon the approval of a user and/or healthcare provider(s).
  • FIG. 30 illustrates wireless communication between a diuretic pen 3001 and a remote control device 3002 which receives biological parameter information from biological parameter measurement device.
  • Measured biological parameter may be input into the diuretic pen wirelessly or manually.
  • a user may input biological parameter manually by using button(s), a knob, etc.
  • the diuretic pen 3001 can contain a processor, software, and telemetry system, though the diuretic pen may not have all of these components or may have additional components.
  • the processor within the diuretic pen can compute the dose of diuretic drug based on the biological parameter.
  • FIG. 32 illustrates examples of sensors/devices measuring various biological parameters. These devices and/or sensors are connected to a diuretic pen wirelessly in some embodiments. The diuretic pen can compute the dose of diuretic injection based on these biological parameters.
  • FIG. 33 shows possible data flow for computation of the diuretics dose.
  • the processor uses various other factors to compute diuretics dose. Examples include physical signs, vital signs, bio markers, symptoms, intracardiac pressure, intravascular pressure, intrathoracic electrical impedance and NYHA classification, etc., as shown in FIG. 33 .
  • BNP B-type natriuretic peptide
  • the diuretic pen can increase (or adjust) the dose of the diuretics.
  • FIG. 34 illustrates another embodiment of the present invention.
  • This figure shows another type of a drug dispensing apparatus.
  • This drug dispensing apparatus is a pen-type apparatus 3406 which contains medication pills 3404 .
  • Some embodiments of this pen-type apparatus contain drug suspension.
  • a user may use this pen-type drug dispensing apparatus 3406 based on “sodium counting.” “Sodium counting” is utilized when a user or a processor of a device calculates the dosage of diuretic based on the amount of sodium intake. For example, a user may be instructed by a physician to use 2 mg of furosemide per 50 mg of sodium intake.
  • the pen-type apparatus might contain multiple 2 mg or 1 mg furosemide pills, though various doses of furosemide can be contained in the apparatus.
  • a user plans to eat 350 mg of sodium, the user can take 14 mg of furosemide according to the “sodium counting.”
  • 14 mg can be input into the pen-type apparatus using a button 3407 and a knob 3401 .
  • knob 3401 is pushed, screw 3403 is moved to push the pills out of the drug container.
  • Screw 3403 movement is controlled by a processor in some embodiments, though screw 3403 movement is controlled manually in other embodiments.
  • the dosage of 14 mg furosemide is not readily available at a pharmacy because 14 mg is not a commonly used dose of furosemide pill. If the pen-type apparatus contains 2 mg furosemide pills, 7 furosemide tablets are taken out of the dispenser.
  • this pen-type drug dispensing apparatus makes it easy to dispense various doses of diuretics and other medications.
  • this pen-type diuretic dispensing apparatus contains a processor which can compute the dose of diuretics when a user inputs the amount of sodium or salt into the pen-type diuretic dispensing apparatus.
  • a user can input the amount of sodium or salt using knob 3401 and/or buttons on the apparatus.
  • knob 3401 when knob 3401 is pressed, a predetermined number of pills are released out of the container 3406 . For example, two tablets of 1 mg furosemide pill can be released out of the container when knob 3401 is pressed.
  • the user may be instructed to press the knob 3401 one time when the user plans to eat food with low salt and/or water content, to press the knob 3401 twice when a user plans to eat food with moderate salt and/or water content, or press the knob 3401 three times when he plans to eat food with high salt and/water content.
  • FIG. 35 illustrates another embodiment of the invention.
  • a disposable external diuretic infusion pump 3501 is attached to the body 3505 of a user.
  • This disposable external diuretic infusion pump includes a reservoir that contains the diuretic.
  • This external diuretic infusion pump 3501 can be a metered dose infusion pump.
  • the external diuretic infusion pump 3501 is set to deliver a predetermined volume of a drug to the user.
  • a button 3502 When the user pushes a button 3502 , a predetermined volume of the drug is delivered via a cannula 3503 to the user.
  • the tip of the cannula 3503 is located subcutaneously in a preferred embodiment.
  • a reservoir may be refilled through a hole 3504 .
  • a metered dose diuretic infusion is as follows. If a user is expected to eat food that contains salt, the user may be instructed to use this metered dose diuretic infusion pump before or at the time of eating this food. For example, a pump may deliver 1 mg of furosemide to the user each time button 3502 is pressed. The user can be instructed to press the button 3502 one time when the user plans to eat food with low salt content, twice when the user plans to eat food with moderate salt content, three times when the user plans to eat food with high salt content. The user may be able to urinate and excrete salt shortly after eating using this device system. People with heart failure are instructed to avoid food with high salt content because of body salt and fluid overload.
  • the metered dose diuretic infusion pump can deliver a diuretic based on measured body weight.
  • the user may be instructed to press the button 3502 once when the measured body weight is 1 kg above target weight, twice when the measured body weight is 1-2 kg above target weight, and three times when the measured body weight is more than 2 kg above target weight.
  • the metered dose drug infusion pump can be implanted under skin in some embodiments.
  • FIG. 36 illustrates another embodiment. It can be important to measure body weight and/or biological parameters regularly, to take electrolyte supplements, such as potassium supplement or magnesium supplement, and to measure blood pressure while a user uses a diuretic infusion pump for safety reasons.
  • electrolyte supplements such as potassium supplement or magnesium supplement
  • FIG. 36 the user is asked if he took potassium supplement, measured his body weight, and measured his blood pressure. If the user inputs “yes,” the diuretic infusion pump is programmed to continue diuretic infusion. If the user inputs “no,” the diuretic infusion pump can be programmed to discontinue diuretic infusion until the user inputs “yes.” This feedback mechanism is a safety feature of the diuretic infusion system.
  • FIG. 37 illustrates examples of sensors/devices measuring various biological parameters. These devices and/or sensors are connected to a remote control device wirelessly in some embodiments.
  • the remote control device can compute the dose of diuretic injection based on these biological parameters.
  • FIG. 38 shows possible data flow for computation of the diuretics dose.
  • the processor uses various other factors to compute diuretics dose. Examples include physical signs, vital signs, bio markers, symptoms, intracardiac pressure, intravascular pressure, intrathoracic electrical impedance and NYHA classification, etc. For example, if B-type natriuretic peptide (BNP) is elevated, this may indicate increased body fluid volume and congestive heart failure. If BNP is above 100 pg/ml, the remote control device can compute the dosage and increase (or adjust) the dose of the diuretics.
  • BNP B-type natriuretic peptide
  • a photograph of the user's legs or other parts of the body can be taken by the diuretic infusion pump system by a camera or a cell phone.
  • the photograph can be transmitted to a healthcare provider.
  • the healthcare provider reviews the photograph of legs, and may be able to verify the body fluid condition by comparing the measured weight with the photograph.
  • the diuretic infusion pump can also have a built-in camera.
  • the healthcare provider can detect malfunction of the weight scale when the measured body weight is far greater than the target weight but the photograph of the legs does not show any swelling.
  • FIG. 39 illustrates another embodiment of the invention.
  • Urinary catheter 3905 is placed into a bladder of a human body 3902 .
  • Urinary catheter 3905 is connected with a drainage bag 3904 .
  • the amount of urine output over a period of time can be measured using this urinary catheter and drainage bag.
  • the urine output measurement system can include a urinary catheter, a drainage bag, a sensor to measure urine output, a transmitter, a receiver, a processor, software, etc., though it can have fewer or more components.
  • the measured urine output over a predetermined period of time is transmitted wirelessly or by other means (e.g., wired, manual data input, etc.) to a diuretic infusion pump 3901 .
  • the diuretic infusion pump 3901 automatically adjusts the infusion rate of diuretic based on the urine output in order to achieve a target urine output.
  • the diuretic infusion pump has a separate a remote control device, a portable computer system, a PDA, etc., which can communicate wirelessly or via other means (e.g., wired, manual data input, etc.) with the urine output measurement system.
  • a physician programs the diuretic infusion pump system to achieve 2400 ml of urine output over a 24-hour period. In order to achieve this, a urine output of 100 ml per hour is required on average over 24 hours.
  • Various diuretic infusion protocols shown in other figures may be programmed into the diuretic infusion pump.
  • the sensor of the urine output measurement system measures the amount of the urine output.
  • the transmitter of the urine output measurement system transmits the urine output information wirelessly or by other means (e.g., wired, manual data input, etc.) to the diuretic infusion pump system and/or a separate computer, a remote control device, etc.
  • the diuretic infusion pump can increase diuretic infusion to increase urine output. If the urine output over a predetermined period of time is greater than the target urine output, the diuretic infusion pump can decrease diuretic infusion to decrease urine output. If the urine output were 80 ml over one hour, the diuretic infusion pump would increase the diuretic infusion to achieve 120 ml over the next hour to achieve 100 ml per hour of urine output.
  • the diuretic infusion pump 3901 can deliver the diuretic intravascularly, subcutaneously, intramuscularly, etc.
  • the diuretic infusion pump 3901 can communicate wirelessly or by other means (e.g., wired, manual data input, etc.) with a non-invasive blood pressure monitoring system 3907 .
  • the non-invasive blood pressure monitoring system 3907 can have a processor, a controller, software, a wireless transmitter/receiver, though it may have fewer or more components in alternative embodiments.
  • the measured blood pressure is transmitted wirelessly or by other means (e.g., wired, manual data input, etc.) to the diuretic infusion pump 3901 .
  • the diuretic infusion pump 3901 can stop the diuretic infusion or adjust the diuretic infusion based on the program. This system may reduce the risk of hypotension.
  • the diuretic infusion pump 3901 can increase diuretic infusion or adjust the diuretic infusion based on the program.
  • the urine output measurement system comprises a urinary catheter, a urine drainage bag, and a sensor to measure urine output, but does not include a wireless transmitter and receiver.
  • the user may input the urine output over a certain period of time manually into a diuretic infusion pump system and/or a separate computer or a remote control device.
  • the diuretic infusion pump system can communicate wirelessly or by other means (e.g., wired, manual data input, etc.) with the urine output measurement system and other biological parameter sensors (see other figures).
  • the diuretic infusion pump system can adjust the diuretic infusion to maintain the target urine output, as well as to maintain the target biological parameter (e.g., the target intravascular pressure, the target intracardiac pressure, and/or the target intrathoracic impedance).
  • the target biological parameter e.g., the target intravascular pressure, the target intracardiac pressure, and/or the target intrathoracic impedance.
  • FIG. 40 illustrates the operation of a diuretic infusion system according to one embodiment.
  • the urine output measurement sensor and processor are onboard, within a housing of the urine output measurement apparatus.
  • the urine output measurement sensor is electrically connected to the processor, and sends the measured urine output to the processor.
  • the processor is connected to a telemetry system and a signal transmitter. The urine output information is sent from the telemetry system of the urine output measurement apparatus via the transmitter.
  • the urine output information signal is received by a receiver of the diuretic infusion pump.
  • the receiver of the diuretic infusion pump is electrically connected to a processor which is housed in the diuretic infusion pump.
  • the processor receives the urine output information and performs computations to determine the diuretic infusion rate, such as basal rate and bolus rate, according to programmed parameters, protocols and algorithms.
  • the processor controls an electric motor to deliver diuretic from a reservoir to a user through an outlet, a tube, and an infusion set of the diuretic infusion pump.
  • the user manually inputs measured urine output into the diuretic infusion device.
  • This urine output information enters a processor which is housed in the diuretic infusion pump.
  • the processor performs computations to determine the diuretic infusion rate as described with regard to other figures.
  • FIG. 41 illustrates the wireless operation of the diuretic infusion pump system.
  • the urine output measurement system 4101 includes a urine output measurement sensor 4102 , a processor 4103 , and a wireless transmitter 4104 (or a wireless receiver), a urinary catheter, a urine drainage apparatus, and an antenna 4105 .
  • the transmitter 4104 sends signals 4106 that contain urine output information.
  • the urine output signal(s) can be sent to different receivers.
  • the diuretic infusion pump receives the signal(s) 4106 through an onboard receiver 4108 via an antenna 4107 .
  • a handheld communication device such as a remote control device, an iPODTM, an MP3 player, a handheld computer, or a portable phone may receive the signal 4106 through an onboard receiver 4112 via an antenna 4111 .
  • the user may choose to send information to a computer or handheld communication device for the purpose of saving urine output information on the computer or connecting with the Internet to send urine output information to healthcare providers.
  • the diuretic infusion pump system and/or handheld communication device can receive biological parameter signal(s) wirelessly or by other means (e.g., wired, manual data input, etc.) from the biological parameter sensor, transmitter, or processor 4110 .
  • FIG. 38 provides examples of biological parameters.
  • FIG. 42 illustrates an example of furosemide infusion protocol based on urine output.
  • FIG. 43 illustrates an ambulatory diuretic infusion pump 4301 mounted at a pole 4310 .
  • a diuretic contained in a bag 4303 is infused into a vein of a patient 4305 through an intravenous tube system 4304 .
  • the diuretic infusion pump 4301 contains a controller which adjusts the rate of diuretic infusion based on urine output and/or other biological parameter(s).
  • a user can input the urine output measured by urine output measurement system 4308 , 4309 using a keypad 4302 or using a remote controller.
  • the urine output measured by the urine output measurement system can be transmitted wirelessly to the diuretic infusion pump 4301 in another embodiment.
  • the blood pressure measured by blood pressure measurement system 4306 , 4307 can be manually input into the diuretic infusion pump 4301 or transmitted wirelessly into the diuretic infusion pump 4301 .
  • FIG. 44 illustrates an ambulatory diuretic infusion pump 4401 mounted at a pole 4402 .
  • a diuretic contained in a bag 4406 is infused into a vein of a patient 4404 through intravenous tube system 4403 .
  • the diuretic infusion pump 4401 contains a controller which adjusts the rate of diuretic infusion based on weight and/or other biological parameters.
  • a user can input the weight measured by weight measurement scale 4405 into the diuretic infusion pump 4401 using a keypad. 4407 or using a remote control device.
  • the weight measured by the scale 4405 can be transmitted wirelessly to the diuretic infusion pump in another embodiment.
  • diuretic infusion pump or “diuretic infusion system” or similar variants” is used in this application, one of ordinary skill in the art would know that this term is not limited to the use of diuretics, but can also use other types of drugs, as well. Thus, this term is not limited to diuretics. Many different drugs can be used for the diuretic infusion pump. Examples of such drugs are described in other parts of the application.
  • Diuretic infusion pumps can contain two reservoirs in some embodiments.
  • One reservoir can contain furosemide.
  • the other reservoir can contain buffering solution.
  • Buffering solution includes (but is not limited to) sodium chloride solution, Lactated Ringer's solution, or Dextrose 5% solution.
  • Some furosemide solution may have a high pH of about 9. Mixing a furosemide solution with a sodium chloride solution, Lactated Ringer's solution or Dextrose 5% solution may lower the pH of the furosemide solution.
  • Furosemide discolors when it is exposed to light. Discolored furosemide is not recommended to be used.
  • a reservoir and cartridge within a diuretic infusion pump may be light resistant to protect furosemide or other drugs from being exposed to the light.
  • the diuretic infusion pump was located external to the body. However, alternatively, internal and implantable diuretic infusion pumps may also be made. The diuretic infusion pumps are also shown as portable in the above description. In alternative embodiments, the diuretic infusion pump may not be portable.
  • a user of the diuretic infusion pump may choose to use the device for long term or may choose to use it for short term when his body weight changes.
  • the diuretic infusion pump can also be used in various locations: home, outpatient facilities and hospitals, as well as the intensive care unit.
  • Programs and protocols coupled with the diuretic infusion pump preferably have various safety measures to minimize side effects of diuretics.
  • a safety measure is that the diuretic infusion pump stops infusing diuretics when a user does not measure body weight in a certain period after previous weight measurements.
  • the diuretic infusion pump may be programmed to stop diuretic infusion in two days if the diuretic infusion pump does not receive a new body weight measurement. This safety measure helps to avoid using inappropriately high dose of diuretics when previously measured body weight is higher than actual body weight.
  • Alarms and display on the screen may be programmed to request a user to enter a new body weight measurement into the diuretic infusion pump.
  • Coupled circuitry can be coupled to each other by hardwiring or by accessing a common register or memory location, for example.
  • Software “coupling” can occur by any number of ways to pass information between software components (or between software and hardware, if that is the case).
  • the term “coupling” is meant to include all of these and is not meant to be limited to a hardwired permanent connection between two components.

Abstract

The system for controlling body fluids overcomes the limitations of the prior art by automatically infusing diuretic and/or other drugs into a human patient. In one approach, the rate of infusion of the diuretic is adjusted based on a measured biological parameter of the patient. For example, this biological parameter can be transmitted wirelessly to a portable diuretic infusion device attached to the patient.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims priority under 35 U.S.C. §119(e) to (a) U.S. Provisional Patent Application Ser. No. 60/967,025, “Apparatus and method to control body fluid balance,” filed Sep. 1, 2007, (b) U.S. Provisional Patent Application Ser. No. 60/979,634, “Controlling body fluid condition using diuretics,” filed Oct. 12, 2007, (c) U.S. Provisional Patent Application Ser. No. 60/986,974, “Controlling body fluid condition using diuretics,” filed Nov. 9, 2007, and (d) U.S. Provisional Patent Application Ser. No. 60/988,375, “Controlling body fluid condition using diuretics,” filed Nov. 15, 2007, and (e) U.S. Provisional Patent Application Ser. No. 61/048,113, “Controlling body fluid condition using diuretics,” filed Apr. 25, 2008. The subject matter of all of the foregoing is incorporated herein by reference in its entirety, including any appendices or attachments, for all purposes.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention relates to controlling body fluid condition using diuretics.
  • 2. Description of the Related Art
  • Body fluid imbalance is associated with many diseases such as congestive heart failure, liver cirrhosis and kidney disease. Congestive heart failure in particular is a major cause of death and hospitalization. Despite currently available treatment, mortality and hospitalization from congestive heart failure remains high. Causes of heart failure include coronary artery disease, hypertension, valvular heart disease, myocardial infarction, etc. As pump function of the heart deteriorates, body fluid often increases and may lead to complications such as pulmonary edema.
  • When pumping capacity of the heart deteriorates, blood perfusion to the kidneys decreases. This results in retention and accumulation of body fluid because excessive body fluid is not delivered to the kidneys to be excreted. This excessive body fluid often manifests as swelling of the legs. If body fluid continues to expand, a weak heart may be no longer able to handle increased blood volume and finally fails to pump blood forward adequately. Symptoms of congestive heart failure include shortness of breath, fatigue, swelling of legs, orthopnea, paroxysmal nocturnal dyspnea (not being able to breathe suddenly at night). Many people come to the emergency room due to congestive heart failure exacerbation. People do not breathe well when fluid builds up in the lungs.
  • Diuretics such as hydrochlorothiazide, furosemide and bumetanide are often used to treat this fluid accumulation by increasing the excretion of body fluid and sodium through the kidneys. However, use of oral diuretics often fails to prevent heart failure exacerbation. This failure of diuretics to prevent heart failure can be explained by several mechanisms. First, the dosage of oral diuretics prescribed by the doctor is often fixed, but the ideal dosage often changes depending on changing body conditions. For example, when people with heart disease eat salty food high in sodium content, their body fluid may increase significantly. We often see people come to the emergency room after they eat excessive amount of salt at a party. In this situation, people will require a higher dose of diuretics in order to excrete excessive body fluid and salt. The required dose of diuretics is affected by the dietary intake of sodium, water and tendency to retain sodium. When body fluid builds up in the digestive system, it may cause intestinal edema (swelling). Bioavailability of diuretics may decrease with intestinal swelling. The body may not be able to absorb diuretics effectively. Patients may need to take higher dose of diuretics when poor bioavailability occurs.
  • Second, poor compliance plays a role. People sometimes forget to take medications. This poor compliance could result in heart failure. Third, treatment delay plays a role. When there is a sign of body fluid accumulation such as swelling of legs, many people ignore this early sign of heart failure and wait until their condition gets severe enough to require hospitalization. These explanations are associated with many cases of heart failure.
  • Sliding scale diuretic titration of oral diuretics has been attempted for the treatment of congestive heart failure by some heart failure management programs. In sliding scale diuretic titration, patients are instructed to measure body weights and adjust diuretics pill dose according to the instruction given by their physician or nurse. However, conventional diuretic sliding scale titration has several significant drawbacks. First, patients may not understand the sliding scale instruction or may not comply with it. Poor understanding of the instruction may also lead to inappropriate use of medication. Second, conventional instructions may be limited to instructions and sliding scale titration that are simpler than would be desired. In real clinical situations, a more complex diuretic titration may be required to maintain ideal body fluid condition. However, some patients may not be able to follow such complex instructions so instructions may be simplified at the cost of a less effective titration.
  • In addition, if the sliding scale diuretic titration changes frequently, some patients may not understand the change of sliding scale diuretic titration and may end up taking the wrong dose of medication. This may lead to serious complications. Taking too much medication may lead to complications such as dehydration, electrolyte imbalance, hypotension, and kidney failure. Conventional sliding scale diuretic titration is also limited to oral diuretics, which may not be as effective as, for example, continuous infusion of diuretics.
  • As a result of these possible complications, sliding scale diuretic titration, when attempted, is typically based on a straightforward and simple protocol. More complex protocols generally have not been attempted because there is not a reliable way to carefully monitor and control the dispensing of diuretic or to adjust the dose according to varying conditions. In addition, there are not reliable safety measures to safeguard against the possible inappropriate use of diuretics. Without such controls and safety measures, more complex protocols can have a higher risk of inappropriate use of diuretics and possible adverse effects such as dehydration, electrolytes abnormalities, hypotension, and kidney failure.
  • Thus, there is a need for better, and preferably automatic, approaches to control body fluid condition using diuretics.
  • SUMMARY OF THE INVENTION
  • One aspect of the present invention overcomes the limitations of the prior art by automatically infusing diuretic into a human patient. In one approach, the rate of infusion of the diuretic is adjusted based on various biological parameter(s) other than body weight, although possibly in combination with body weight. The biological parameter(s) can be transmitted wirelessly to a portable diuretic infusion device attached to the patient, for example.
  • In one aspect of the invention, a portable diuretic infusion device includes a reservoir, a pump and a controller. The reservoir can hold a diuretic or an antihypertensive drug to be infused into the patient. The pump is connected to the reservoir and is also connectable to the patient, for example using an infusion set. The pump is operated to infuse diuretic or other drug from the reservoir into the patient. The controller controls the pump based on some biological parameter(s), thereby controlling the rate of infusion of the diuretic or other drug.
  • In one embodiment, the controller adjusts the rate of infusion based on a measured intrathoracic electrical impedance of the patient. For example, the protocol may be designed to maintain a target intrathoracic electrical impedance for the patient, so that more diuretic is infused when the patient is over the target and less diuretic is infused when the patient is under the target. In another aspect, the patient's intrathoracic electrical impedance can be measured by an implantable device and then wirelessly transmitted to the diuretic infusion device. The controller on the diuretic infusion device receives the intrathoracic electrical impedance information and automatically adjusts the infusion rate.
  • In another aspect of the invention, the diuretic infusion device adjusts the diuretic infusion rate based on various biological parameter(s). These biological parameters can include, for example, vital signs, blood pressure, intracardiac pressure, intravascular pressure, biomarker(s), physical sign(s), weight, NYHA classification, and/or symptoms,
  • In still a further aspect of the invention, the diuretic infusion system includes a biological parameter measurement apparatus with a biological parameter measurement sensor for measuring a biological parameter of a human patient and a wireless transmitter for wirelessly transmitting measured biological parameter information. The diuretic infusion system also includes a portable diuretic infusion device with a reservoir for holding diuretic, a pump connected to the reservoir and connectable to the human patient, for infusing diuretic from the reservoir into the human patient, a wireless receiver for wirelessly receiving the biological parameter information transmitted by the biological parameter measurement apparatus, and a controller coupled to the wireless receiver, for controlling the pump and rate of infusion of the diuretic based on the received biological parameter information.
  • In further embodiments, the diuretic infusion system is remote control operated. The system can include a biological parameter measurement apparatus having a sensor for measuring a biological parameter of a human patient and a wireless transmitter for wirelessly transmitting biological parameter information based on the measured biological parameter. The system can further include a portable diuretic infusion device with a reservoir for holding diuretic, a pump connected to the reservoir and connectable to the patient, a controller for controlling the pump, and a wireless receiver for wirelessly receiving commands. The system can also include a remote control device with a wireless receiver for wirelessly receiving the biological parameter information transmitted, a wireless transmitter for wirelessly transmitting one or more commands to the portable diuretic infusion device, and a controller coupled to the receiver/transmitter for wirelessly controlling the pump and rate of infusion based on weight information. Other embodiments of the diuretic infusion system can include fewer or more components within the biological parameter measurement apparatus, the portable diuretic infusion device, and the remote control device.
  • In yet another embodiment, the diuretic infusion system includes a urine output measurement apparatus with a urinary catheter, a urinary drainage apparatus, and a urine output sensor for measuring urine output of a human patient. In some embodiments, the urine output measurement apparatus also includes a wireless transmitter for wirelessly transmitting urine output information based on the measured urine output. The system can also include a portable diuretic infusion device with a reservoir for holding diuretic, a pump connected to the reservoir and connectable to the patient for infusing diuretic from the reservoir into the patient, and a controller that controls the pump, thereby controlling a rate of infusion of the diuretic based on received urine output information. Where the urine output measurement apparatus is configured for wireless communication, the portable diuretic infusion device can include a wireless receiver for wirelessly receiving the urine output information transmitted from the urine output measurement apparatus. In some embodiments, the infusion system further includes a remote control device with a wireless receiver for wirelessly receiving the urine output information transmitted from the urine output measurement apparatus, and a wireless transmitter for wirelessly transmitting one or more command to the portable diuretic infusion device. The remote control device can also include a controller coupled to the wireless receiver and transmitter for wirelessly controlling the pump and rate of infusion of the diuretic based on the received urine output information
  • Different protocols can be implemented using these devices and systems. For example, the infusion rate can include both basal and bolus components. Diuretic infusion can be supplemented and/or replaced by other delivery mechanisms, such as oral diuretics. Fairly complex protocols can be implemented, since the protocol is more automated and depends much less on the patient implementing the protocol. For example, infusion rate can vary by time of day, thus reducing urination at nighttime. Prospective infusion can also be implemented, for example if heavy salt intake is expected. The infusion rate can also be adjusted based on feedback other than just weight.
  • These approaches allow the dose of diuretics to be controlled much more carefully than by patient instructions alone, resulting in many possible advantages. For example, early detection and early treatment of various body fluid related diseases may be possible. This can reduce hospitalizations and death from congestive heart failure, pulmonary edema and fluid overload. In addition, patients can now have continuous infusion of diuretics by using a portable, ambulatory infusion pump. Continuous infusion of diuretics may be more effective than bolus use of diuretics. These approaches may also be more effective in maintaining target weight and/or dry weight, compared with using oral diuretics. The automated approach is also easier for patients and allows the implementation of more complex protocols, while also reducing the risk of over- or under-treatment. The automated devices can also record diuretic use (and also body weight), thus providing a reliable medical history. This information can be sent over the internet to the healthcare providers or others, for analysis or remote monitoring of patients.
  • Other aspects of the invention include methods corresponding to the devices and systems described above, and protocols for use with same.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention has other advantages and features which will be more readily apparent from the following detailed description of the invention and the appended claims, when taken in conjunction with the accompanying drawings, in which:
  • FIGS. 1 depicts a diuretic infusion system.
  • FIG. 2 depicts a more detailed view of a diuretic infusion device.
  • FIG. 3 is a block diagram of a diuretic pump.
  • FIGS. 4 and 5 are a mechanical depiction of a diuretic pump.
  • FIG. 6 is a mechanical depiction of a diuretic pump with two reservoirs.
  • FIG. 7 shows data flow for computation of diuretic infusion rate.
  • FIG. 8 illustrates infusion of diuretic into the body.
  • FIG. 9 is a mechanical depiction of another diuretic pump.
  • FIGS. 10-11 further illustrate operation of further embodiments for diuretic dispensing.
  • FIG. 12 illustrates further embodiments for a diuretic infusion system.
  • FIG. 13 illustrates another diuretic infusion system.
  • FIGS. 14 and 15 show protocols for use with the diuretic infusion system of FIG. 13.
  • FIG. 16 illustrates another diuretic infusion system including an electric scale.
  • FIGS. 17-20 show protocols for use with the diuretic infusion system of FIG. 16.
  • FIG. 21-22 illustrates another diuretic infusion system including an implantable device.
  • FIG. 23 shows a protocol for use with the diuretic infusion system of FIG. 21.
  • FIG. 24 illustrates another diuretic infusion system including a remote control device.
  • FIG. 25 illustrates a more detailed view of the diuretic infusion device and the remote control device.
  • FIG. 26 illustrates the operation of a closed loop drug infusion system for a diuretic infusion pump system.
  • FIG. 27 illustrates wireless communication of a diuretic infusion pump system with biological parameter measurement apparatuses.
  • FIG. 28 a diuretic infusion device with a patch sensor system.
  • FIG. 29 illustrate additional drug-infusion protocols
  • FIG. 30 illustrates a wirelessly-operated diuretic injecting pen-type device.
  • FIG. 31 illustrates the components of the diuretic injecting pen-type device.
  • FIG. 32 illustrates examples of the biological parameters measured by devices or sensor communicatively coupled to the diuretic injecting pen-type device.
  • FIG. 33 illustrates a data flow for computation of the diuretics dose for the diuretic injecting pen-type device.
  • FIG. 34 illustrates another type of drug-dispensing pen-type apparatus for dispensing pills.
  • FIG. 35 illustrates a disposable external diuretic infusion pump.
  • FIG. 36 shows another embodiment of a diuretic infusion pump with a feedback mechanism.
  • FIGS. 37 and 38 show various biological parameters and factors that may be used with various embodiments, such as that of FIG. 25.
  • FIG. 39 illustrates a diuretic infusion system including a urine output measurement apparatus.
  • FIG. 40 illustrates the operation of the system of FIG. 39.
  • FIG. 41 illustrates a wirelessly operated diuretic infusion system with urine output measurement apparatus.
  • FIG. 42 illustrates an example of a furosemide infusion protocol based on urine output.
  • FIG. 43 illustrates an ambulatory diuretic infusion pump with urine output measurement apparatus.
  • FIG. 44 illustrates another ambulatory diuretic infusion pump.
  • The figures depict embodiments of the present invention for purposes of illustration only. One skilled in the art will readily recognize from the following discussion that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles of the invention described herein.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • FIG. 1 depicts a diuretic infusion system according to the invention. Diuretic infusion device 101 is located on the patient's body 102. Weight sensor 103 measures the patient's body weight. In one embodiment, the weight sensor 103 is an electric scale. A user inputs measured body weight into the diuretic infusion device 101. The diuretic infusion device 101 delivers diuretic to the human body 102. The dose of the diuretic is determined based on the measured body weight.
  • Various diuretics may be used with the diuretics infusion device. Examples include hydrochlorothiazide, chlorothiazide, chlorthalidone, metolazone, furosemide, bumetanide, ethacrynic acid, torsemide, spironolactone, indapamide and eplerenone. Vasopressin receptor antagonist may also be used. Examples include conivaptan, tolvaptan. Brain natriuretic peptide may also be used. One example is nesiritide.
  • FIG. 2 is a close-up of the diuretic infusion device 101 of FIG. 1. In this example, the diuretic infusion device 101 is a diuretic pump 201 that is attached to the body 207. A preferred location is around the body waist and abdomen. The size of the diuretic infusion pump can vary. In one implementation, the diuretic pump is 2.2×3.7×1 inches. This diuretic infusion pump 201 includes a wireless communications chip, processing module, batteries and processor (see FIG. 3 for further detail). The diuretic infusion pump 201 may not include the wireless communications chip in alternative embodiments.
  • An external keypad to allow the user to program an onboard processor. The onboard processor controls the rate of diuretic infusion. Various buttons 202, 203 are used for various functions, such as programming the diuretics pump and adjusting the diuretic infusion rate. Information such as rate of diuretic infusion, name of diuretics in use, weight information, and optimal or target weight, can be displayed on the screen 204. This screen also shows signals that indicate malfunction of the device and other signals such as time to change a diuretics cartridge or time to change a battery.
  • This diuretic infusion pump 201 includes a disposable reservoir or a disposable cartridge for the diuretic. The prefilled cartridge containing diuretics is replaced when empty. In alternative embodiments, the reservoir and/or cartridge may not be disposable. Instead, the reservoir may be refilled when empty.
  • A disposable infusion set for the diuretic infusion pump may include a cannula 209, an adhesive pad 205, a needle 208 and tubing system 206 (that delivers the diuretic reservoir to a user). The user inserts the needle 208 together with the cannula 209 under the skin. The needle 208 may be removed, leaving the cannula 209 under the skin. Preferably, the tip of the cannula 209 is located at the subcutaneous tissue. Alternatively, the tip of cannula 209 may be located in the abdominal cavity, intramuscular space, intravascular space or peritoneal cavity. The cannula 209 may be made with biocompatible materials such as polyethylene.
  • FIG. 3 is a block diagram of a diuretic pump. Processor 301 (the controller) is contained in the interior of the housing 316 of the diuretic infusion pump. The housing 316 may be made of plastic or steel, for example. Processor 301 runs software programs and controls components of the diuretics infusion pump. The Freescale Dragonball microprocessor is one example of a processor that may be used. The Motorola 6805 is another example. The Freescale MC9S08RX32A is another example. The MC9S08RX32A includes an RF integrated circuit and microcontrollers (MCU). Other processors that are used in insulin pumps may also be used.
  • The processor 301 is in electrical communication with an electric motor and pump 313. The processor controls the electric motor 313 according to its program. The processor also controls a screen 304, an audible alarm 307, vibratory alarm 308 and telemetry system. Weight information that is transmitted from the weight measurement apparatus is received by the telemetry system of the diuretic infusion pump. It then enters the processor 301. Alternately, weight information may be input into the diuretic infusion pump manually by a user, for example from a keypad or a remote controller.
  • In this example, flash memory 314 and SRAM 315 are used for memory storage. This memory may store information such as pump settings, a historical log of weight, malfunctions of the pump, infusion rate, a historical log of infusion rate, medication, etc. In one design, the RAM has 100 kilobytes, ROM has 4 megabytes and flash memory has 4 megabytes memory. Alternate memory media include RAM, ROM, EPROM, DRAM, hard-drives and other types of flash memory.
  • The user may program the processor 301 using a keypad (or other user interface) on the diuretic infusion pump. In alternative embodiments, a user may use a remote controller or a computer station to program the processor 301.
  • Information and commands from other computers, portables devices such as PDAs (personal digital assistant), handheld computers, portable phones, remote controllers and the internet may be received through receiver 303. Examples of wireless technologies include radio frequency (RF), infrared (IR) and optical. Specific technologies include Bluetooth, DECT, ZigBee, NFC, GSM, UWB, UMTS, DAB, CDMA, WiFi and WIMAX. Wired communications ports can include Universal Serial Bus (USB) ports and/or RS-232 ports, as well as other technologies.
  • The diuretic infusion pump displays on its screen whether new weight information, command, or alerts are received. The diuretic infusion pump, weight measurement apparatus, corresponding computer systems and/or remote controller may be assigned a unique identifier and/or password to provide privacy for its users.
  • In FIG. 3, a keypad 309 is located on the housing 316. A touch screen input device may also be used. The keypad 309 shown in FIG. 2 includes buttons 203, 202 to provide input to the processor 301.
  • Various other inputs, such as various types of sensors, may also be included in the diuretic infusion pump (or communicate to the diuretic pump from other parts of the system). For example, motion detection sensor 312 may be used to detect the motion of a gear in the drive mechanism for the pump. Cartridge sensor or reservoir sensor 311 may be used to detect the amount of diuretic left within a cartridge or reservoir, and to notify a user when a new cartridge is required or a reservoir requires refilling.
  • In one embodiment, LCD is used as a screen. Feedback from the weight measurement apparatus, a computer, a remote control device as well as diuretic infusion pump status and programming changes may be displayed on a LCD screen. Time, name of drug, dose of drug used during a particular period of time, reservoir or cartridge usage and history may also be displayed.
  • A speaker can be used to send audio feedback. A user may choose to use a vibratory alarm instead of audible alarm. For example, if measured body weight is too low or too high, an audible or vibratory alarm may warn a user. If measured body weight is lower than a set value, a certain instruction such as “Drink more water and eat more because you may be dehydrated” may be shown on the screen or played through the speaker. When measured body weight is higher than a set value, certain instructions may be expressed, such as “Calibrate your weight measurement scale” or “Call your doctor if you feel shortness of breath.” Alarms may also be activated for pump malfunction, low battery, dead battery, occlusion of infusion set, near-empty cartridge (or reservoir), pump delivery error, if bolus is changed, if mode is changed, if pump is not primed, if infusion exceeds maximum limits, etc.
  • The diuretic infusion pump preferably uses a AAA alkaline battery. More than one AAA alkaline batteries may be used. Alternatively, different types of batteries may be used such as nickel cadmium battery, nickel metal hydride battery, lithium ion battery, carbon battery, lithium battery and 3.6V lithium battery. The battery may be included inside the housing 316 of the diuretic infusion pump.
  • Not all embodiments require all of the components described above.
  • FIG. 4-5 are mechanical depictions of a diuretic pump. The diuretic infusion pump contains a processor 401. The processor is electrically connected or otherwise communicatively coupled to an electric motor 402, for example a DC motor with gear-reducer. The processor 401 controls the electric motor 402 according to its programming. The electric motor 402 is connected to a peristaltic pump 404. The peristaltic pump 404 has a rotor inside. A flexible tube inside the peristaltic pump 404 is connected with a tube 405 and 408. The flexible tube is in contact with the rollers. When the rotor turns, one or more rollers squeeze and release the flexible tube to deliver drug from a reservoir 403 to a user via the infusion tube 408. In order to detect if the diuretics solution is depleted and needs to be replaced or refilled, a sensor 409 can be used. FIG. 5 is a simplified mechanical depiction of a syringe pump system. The pump housing 515 contains a syringe 516. The syringe 516 contains diuretics. The processor 510 is electrically connected or otherwise communicatively coupled to an electric motor 511. The processor 510 controls the electric motor 511 according to its programming. The motor 511 rotates a motor gear which moves a screw 513 axially. A screw 513 is configured to move axially to push a plunger 514 inside a syringe and push diuretics out of a syringe 516 or a reservoir through an infusion tube 518 and a cannula 519. The plunger mechanism transfers the diuretics solution from a diuretics cartridge or reservoir through an outlet of the housing to the patient via tubing system 405, 408 and the infusion set. Technologies used in insulin pumps may be used also for diuretic pumps.
  • In alternative embodiments, more than one type of drug may be used in the diuretic infusion pump. A processor may be coupled with more than one program, software, protocols and/or parameters that are tailored according to the specific drug that is used. The diuretic infusion pump may automatically recognize the inserted drug. Drug reservoir or cartridge may have a unique identification code. One example of a drug name recognition method is to decode the bar code of the drug name, which is attached on the reservoir or cartridge. Alternatively, the name of the inserted drug may be manually put into the diuretic infusion pump using the keypad which can select alphabets on the screen.
  • Examples of medications that may be contained in the reservoir 807 or cartridge include hydrochlorothiazide, chlorothiazide, chlorthalidone, metolazone, furosemide, bumetanide, ethacrynic acid, torsemide, spironolactone, eplerenone, vasopressin receptor antagonists, conivaptan, tolvaptan, brain natriuretic peptide, and nesiritide.
  • FIG. 6 is a mechanical depiction of a diuretic pump with two reservoirs: in this case a diuretics reservoir 601 and an insulin reservoir 602. Patients with diabetes may also have congestive heart failure. This device delivers both diuretics and insulin using one ambulatory infusion pump. In embodiments that use two reservoirs, each medication is delivered via tubes 603, 604 inside an ambulatory infusion pump and leaves the housing of the pump via a tube 609 outside the ambulatory infusion pump. There may be two separate channels within the tube 609 through which each medication is delivered separately. Each medication is delivered to a user through different holes 611, 612. In alternative embodiments, a syringe pump system can be used instead of a peristaltic pump 606. Two syringes can have separate electric motors that control the movement of the plunger of the respective syringes and release of each medication.
  • Some medications may not be compatible each other so these medications may need to be delivered through separate channels. More than two medications, channels and holes may be used in alternative embodiments. A processor 610 controls an electric motor 605 and a pump 606 according to its program. More than two electric motors and pumps may be used in alternative embodiments. A separate electric motor and pump may be used to deliver different medications in alternative embodiments.
  • FIG. 7 shows possible data flow for computation of the diuretic infusion rate. In preferred embodiments, the processor of the diuretic infusion pump uses weight to compute the diuretics infusion rate. In alternative embodiments, the processor may use various other factors to compute diuretic infusion rate. Examples include physical signs, vital signs, bio markers, symptoms, intracardiac pressure, intravascular pressure, intrathoracic electrical impedance and New York Heart Association (NYHA) classification, as shown in FIG. 7. For example, if BNP (B-type natriuretic peptide) is elevated, this may indicate increased body fluid volume and congestive heart failure. If BNP is above 100 pg/ml, the diuretic infusion pump may increase (or adjust) the infusion rate until the levels returns to normal.
  • ANP (Atrial natriuretic peptide), CNP (C-type natriuretic peptides), NT-pro BNP, ventricular natriuretic peptides and other bio markers that indicate volume overload and heart failure may also be used to compute the diuretic infusion rate.
  • Physical signs of volume overload, such as ankle swelling, leg swelling, arm swelling, and abdominal distension can also be used. For example, a user may use a scale of one to four in body swelling as one being no swelling, four being severe swelling, three being moderate swelling, two being mild swelling. The diuretic infusion pump might adjust the infusion rate to return body swelling to the zero score condition of no swelling. The diuretic infusion pump may also adjust the infusion rate based on blood pressure.
  • The diuretic infusion pump may also adjust the infusion rate by using symptom scores such as a shortness of breath scale (one to four, one-no difficulty breathing, two-mild difficulty, three-moderate difficulty, four-severe difficulty) or a walking scale (one- can walk without limitations, two-can walk less than one block, three-can barely walk even inside home).
  • The diuretic infusion pump may use the NYHA (New York Heart Association) classification to compute the diuretics infusion rate. The NYHA classification is widely used to assess the stage of heart failure. The diuretic infusion pump may adjust diuretics infusion rate to improve patient condition from class II, III or IV to class I.
  • Combinations of variables may be used for the computation of diuretic infusion rate and/or dose. These variable(s) may be used for the computation of the dose and/or infusion of other drugs. Some examples of these drugs include, but not limited to, anti-hypertensive drug, inotropic agents, and anti-arrhythmic drugs.
  • Adjusting the diuretic dose according to intracardiac pressure or central vein pressure is another possibility.
  • FIG. 8 illustrates infusion of diuretic into the body. In FIG. 2, diuretic medication is infused into subcutaneous tissue. In alternative embodiments shown in FIG. 8, diuretic medication may be infused into a peritoneal cavity, an intravascular space (e.g., into a vein) or intramuscularly. The diuretic infusion pump 807 attaches to a tubing system 806, an adhesive 805 and a needle 803.
  • A plastic tube 801 (a catheter) is attached to a silicone bubble 804 (septum). Tip 808 of the plastic tube may be located into a peritoneal space or a vein (or an artery). A needle 803 is inserted into the silicone bubble. Medication is delivered from the infusion pump 807 through a tubing system 808, a needle 803 and a plastic tube 801 into a target space of a user. Examples of a target space include a peritoneal space, a vein, an artery and a muscle. A port 802 and silicone bubble 804 may be located in subcutaneous tissue or may be located outside the skin.
  • FIG. 9 is a mechanical depiction of yet another diuretic pump. More than two drugs may be infused in alternative embodiments. Two drugs are contained in the separate drug reservoir or cartridge. One example of two drugs that may be used includes diuretics and insulin. Another example of two drugs that may be infused includes loop diuretics and thiazide diuretics. Other examples of two drugs that may be used includes “loop diuretics and vasopressin receptor antagonist”, “thiazide diuretics and vasopressin receptor antagonist”, “loop diuretics and potassium sparing diuretics”, “thiazide diuretics and potassium sparing diuretics” and “loop diuretics and carbonic anhydrase inhibitor.” Using the combination of diuretics with a different site of action may be more effective than using only one type of diuretic. Loop diuretics act on the ascending loop of Henle in the kidney. Thiazide diuretics act on distal convoluted tubule in the kidney. Examples of vasopressin receptor antagonists include conivaptan and tolvaptan.
  • FIG. 6 shows an infusion pump with two drug reservoirs 601, 602 that share one pump 606. FIG. 9 shows two peristaltic pumps 903, 904 connecting with two different reservoirs 901, 902. A processor 905 is electrically connected with electric motors 911, 912. The processor 905 controls these electric motors 911, 912 and pumps 903, 904 to deliver medication from each medication reservoir 901, 902. The pump 903 is connected with a reservoir 901 and delivers a medication from a reservoir 901 through a tubing system 906, 908 to a user. The pump 904 is connected with the reservoir 902 and delivers medication from the reservoir 902 through a tubing system 907, 909 to a user.
  • In this example, the tube 908 merges with tube 909. However, there are different channels within the tube to deliver each medication through different channels to prevent mixture of non-compatible medications. These two medications are delivered through separate openings 910, 913. Two medications may be delivered according to two separate programs, protocols, parameters.
  • In alternative embodiments, a diuretic inhaler may be used. Examples include a furosemide inhaler, a bumetanide inhaler, and so forth. If measured body weight is above a previously set target weight, the display on the weight measurement apparatus, the diuretic inhaler or a separate device may show instructions on the dose of drug to be inhaled. For example, if measured body weight is one kilogram above the target weight, a user may be instructed to have one extra-inhalation of furosemide. Other diuretic inhalers, including (but not limited to) furosemide, bumetanide, and torsemide, may be used in alternative embodiments.
  • FIGS. 10 further illustrate operation of other embodiments. In FIG. 10, the diuretic infusion device has various other functions that may improve the health of patients. For example, if intravascular pressure increases due to increased body fluid, it helps to remind patients to control the amount of salt (sodium) that they take daily. The display 1002 shows instructions to avoid food high in sodium chloride. This device may also provide a list of foods high in sodium content, low in sodium content, high in potassium, magnesium, calcium, and/or low in potassium, magnesium, calcium. Diet information may be provided for educational purposes. In alternative embodiments, the device may have a scanner to scan food to notify users whether scanned foods are appropriate for users to take or not. The data (e.g. images) obtained from food scanning may be compared with data saved in the database within the diuretic infusion device to retrieve information on the scanned food. If the scanned food is high in sodium content, instruction to avoid this food may be shown on the display of the diuretic infusion pump. The food scanning can be performed by a separate device such as PDA, a handheld computer, a remote control device, a portable phone, an iPHONE™, an iPOD™, and so forth.
  • The diuretic infusion device may also be connected with a blood pressure cuff, either wirelessly or in a wired manner. Blood pressure information measured by the blood pressure cuff is transmitted to the diuretic infusion pump. Certain instructions may be provided on the display 1002. See FIG. 16. A database of references on health topics, drug information, emergency instruction, BLS (basic life support) may be saved in the memory within diuretic infusion device or diuretic dose instruction device and can be viewed on the display of the device. Examples of instructions include reminding a user to take antihypertensive medications as scheduled, instructing a user to adjust the dose of antihypertensive medications if blood pressure is low or high. If a user develops chest pain, shortness of breath or other urgent medical conditions, the user may be instructed to call his doctor or go to the nearby emergency room or call 911. A user may press an emergency button 1003 to notify family, help agent, 911 or hospital for help during emergent situations. These various functions may be programmed by a healthcare provider.
  • Instructions to take potassium supplement, magnesium supplement and other electrolyte supplement may be displayed on the screen. These electrolytes may be lost by the kidneys as diuretics dose increases. In FIG. 10, a user is instructed to take potassium chloride (KCL) 20 meq. See also FIG. 35.
  • FIGS. 12 and 14 show additional protocols for diuretic dispensing.
  • FIG. 11 illustrates another example. Diuretic infusion pump 1101 has a screen 1 102. A user uses a keypad to edit target intravascular pressure information. The target intravascular pressure is displayed on the screen. A cursor is located on the number of the intravascular pressure. In this FIG. 11, it is located on the digit 12 1103. A user can choose different number using scrolls 1104, 1105. S button 1106 is pressed to select a number. The current intravascular pressure can be manually put into the diuretic infusion pump in a similar manner.
  • In FIG. 12, a furosemide infusion protocol is shown on the screen 1201 of the diuretic infusion pump 1202. The underlined numbers can be changed using scroll buttons 1203, 1204. If scroll button 1203 is pressed, the number increases. If scroll button 1204 is pressed, the number decreases. The cursor is located on underlined thick number 1207, which is a 8. If scroll button 1203 is pressed once, the 8 changes to 9. If scroll button 1204 is pressed once, the 8 changes to 7. If button S 1205 is pressed, the number is selected. If button S is pressed when number 1207 is 8, the 8 is selected and cursor moves on to next underlined number 1208. If all numbers are selected, button M is pressed to move on to another menu.
  • FIG. 13 illustrates another diuretic infusion system. An implant 1304 is located under the skin of human body 1301. The tip of the wire of the implant is located inside a cardiac chamber 1302 to monitor intracardiac pressure. The tip of the wire of the implant may be located in a central vein, pulmonary artery or other vessel in alternative embodiments. A pressure measuring sensor is attached to the tip or other portion of the wire of the implant. The implant may be coupled with a processor, wireless communication module, a controller and a software program. The diuretic infusion pump 1303 communicates wirelessly with the implant 1304 that monitors intracardiac pressure and/or central vein pressure. If the pressure is elevated inside the cardiac chamber or central vein, this may indicate a sign of volume overload. The diuretic infusion pump may adjust its infusion rate according to the pressure measured by this implant.
  • In one approach, a user inputs a target pressure into the diuretic infusion pump. The diuretic infusion pump adjusts its infusion rate to maintain the target pressure. One example of a suitable implant is the Chronicle heart monitor made by MEDTRONIC™. In alternative embodiments, a pacemaker, an automatic implantable cardioverter defibrillator (AICD), or a cardiac resynchronization therapy (CRT) device may be coupled with the pressure measuring sensor, wireless communication module, processor and software program to transmit pressure signals to the diuretic infusion pump.
  • FIG. 14 illustrates a diuretics protocol that may be used with the diuretic infusion device of FIG. 13. A pressure monitoring sensor is located in the central vein, for example the superior vena cava. The implant shown in FIG. 13 transmits a pressure signal wirelessly to the diuretic infusion pump. The diuretic infusion pump adjusts the diuretic infusion rate according to the pressure measured by the pressure monitoring sensor, as shown in FIG. 14. The diuretic infusion pump adjusts the infusion rate to maintain a target pressure within the cardiac chamber, central vein or other vessel. Various other protocols may be used to adjust diuretic infusion according to the pressure. The pressure signal can also be used to trigger safety measures. For example, the diuretic infusion device can be programmed to automatically stop infusion and notify a user if the blood pressure falls below a previously set value. This is to avoid hypotension that may occur with use of high dose diuretics. For example, a diuretic infusion pump may be programmed to automatically stop infusion and notify the user (and/or doctor), if the systolic blood pressure is below 90 mmHg. Various non-invasive biological parameter measurement device such as a patch sensor system, a non-invasive central aortic pressure measurement device, a non-invasive intravascular blood pressure measurement device may be coupled with a diuretic infusion pump wirelessly or via other means such as manual data input and wired communication.
  • FIG. 15 shows another example of furosemide protocol. A blood pressure monitoring sensor located in a central vein can transmit a measured blood pressure signal to the diuretic infusion pump. The diuretic infusion pump displays the instructions regarding the dosage of oral furosemide.
  • FIG. 16 depicts another embodiment of the present invention. A blood pressure cuff 1604 is attached to an arm of a human body 1602. The blood pressure cuff 1604 can be connected to a blood pressure measuring device 1605. The blood pressure measuring device 1605 can be coupled to a processor, wireless communication module, a controller and a software program, though it may not be coupled to all of these in some embodiments. The diuretic infusion pump 1601 can communicate wirelessly or via other means with the blood pressure measuring device 1605. In alternative embodiments, the blood pressure measuring device 1605 can communicate wirelessly or via other means with an electric scale 1603. In alternative embodiments, a user manually inputs measured blood pressure into a diuretic infusion device or a remote control device.
  • FIG. 17 illustrates another example of a furosemide infusion protocol. As shown in FIG. 16, the diuretic infusion pump receives the measured blood pressure wirelessly from the blood pressure measurement device. If the measured blood pressure is below a set blood pressure, the diuretic infusion pump can be programmed to stop furosemide infusion automatically to prevent hypotension, dehydration.
  • FIG. 18 illustrates an example of a furosemide and enalaprilat infusion protocol. As shown in other figures, the diuretic infusion pump can contain more than one drug reservoir. In this example, the diuretic infusion pump has one reservoir containing furosemide and another reservoir containing enalaprilat. Enalaprilat is an angiotensin converting enzyme (ACE) inhibitor which is an antihypertensive drug. The protocol in FIG. 45 shows the diuretic infusion pump infusing enalaprilat as well as furosemide according to measured blood pressure to maintain target blood pressure.
  • FIG. 19 illustrates another example of a furosemide and enalaprilat infusion protocol. The diuretic infusion pump adjusts the infusion rate and a dose of enalaprilat and furosemide according to the measured blood pressure to maintain target blood pressure.
  • FIG. 20 illustrates an example of furosemide and metoprolol infusion protocol. Metoprolol is a beta blocker which lowers blood pressure and heart rate. The diuretic infusion pump may contain one reservoir containing furosemide and one reservoir containing metoprolol. The diuretic infusion pump adjusts the infusion rate and dose of metoprolol and furosemide according to the measured blood pressure to maintain target blood pressure. The diuretic infusion pump may adjust the infusion rate and dose of metoprolol to maintain target heart rate. A patient with heart disease may develop arrhythmia, such as supraventricular tachycardia (rapid heart rate), atrial fibrillation, or ventricular tachycardia. The diuretic infusion pump can infuse metoprolol to lower heart rate. In alternative embodiments, the diuretic infusion pump can communicate wirelessly with an implantable cardioverter defibrillator (ICD), a pacemaker. If an ICD or a pacemaker detects arrhythmia, the ICD or pacemaker can send this arrhythmia information wirelessly or via other means to the diuretic infusion pump. The diuretic infusion pump may infuse an anti-arrhythmic drug to treat the arrhythmia. Examples of anti-arrhythmic drugs include, but are not limited to, amiodarone, metoprolol, sotalol, esmolol, lidocaine, disopyramide, propafenone, dofetilide, flecainide, procainamide and atropine. The diuretic infusion pump may contain and infuse only anti-arrhythmic drug communicating with an ICD or a pacemaker in alternative embodiments.
  • In another embodiment, a user can use one reservoir that contains diuretics and a second reservoir that contains an inotropic drug that increases blood pressure. Examples of inotropic drugs include (but are not limited to) dopamine, dobutamine, phosphodiesterase inhibitor, amrinone, milrinone, enoximone, pimobendan, levosimendan, calcium sensitizing agent, venarinone, and ibopamine. In alternative embodiments, the diuretic infusion pump contains a combination of antihypertensive drugs, inotropic agents, diuretics, and it adjusts the infusion rate according to blood pressure measured by non-invasive blood pressure measurement device and/or measured body weight.
  • FIG. 21 depicts another embodiment. An implantable device 2104 has a pair of electrodes on the surface. The implantable device 2104 is connected to a cardiac ring electrode or coil electrode positioned in the heart 2105 in the human body 2101 via a wire 2102. Intrathoracic impedance between the implantable device case and the right ventricular lead can be measured multiple times a day. If the intrathoracic impedance decreases, this may suggest fluid is accumulating in the lungs due to worsening heart failure. The implantable device 2104 can be a pacemaker, an implantable cardioverter defibrillator, or a cardiac resynchronization therapy device. One example of a suitable implant is OptiVol fluid status monitoring device from Medtronic. The diuretic infusion pump 2103 can communicate wirelessly with the implantable device 2104. The diuretic infusion pump 2103 can adjust the infusion rate of diuretics according to the measured impedance to maintain the target impedance. FIG. 49 illustrates an example of a furosemide infusion protocol according to measured intrathoracic impedance. The diuretic infusion pump may adjust the infusion rate of diuretics according to the average of impedance measurements taken over a predetermined period of time to maintain target measured average impedance.
  • FIG. 22 depicts another embodiment. The diuretic infusion pump 2203 receives weight information wirelessly or manually from a weight measurement device 2201 and communicates wirelessly with the implantable device 2204 which was shown in FIG. 21.
  • FIG. 23 illustrates an example of a furosemide infusion protocol according to measured intrathoracic impedance. The diuretic infusion pump may adjust the infusion rate of diuretics according to the average of impedance measurements taken over a predetermined period of time to maintain target measured average impedance.
  • FIG. 24 illustrates another embodiment. A diuretic infusion device 2401 is attached to a human body 2402. This portable diuretic infusion device 2401 delivers diuretics from a reservoir to the human body 2402. The diuretic infusion device 2401 may be smaller in size compared to other embodiments shown in other figures. This diuretic infusion device 2401 can be disposable. The diuretic infusion device 2401 contains a reservoir, a programmable processor, an exit port, a cannula and a motor, though some embodiments may contain fewer components or additional components. The diuretic infusion device 2401 can communicate wirelessly or via other means with a remote control device 2404. The remote control device 2404 can communicate wirelessly with an intrathoracic impedance measurement device 2405 and a diuretic infusion device 2401 in one embodiment. The remote control device 2404 may communicate wirelessly with only the diuretic infusion device 2401, and not with the intrathoracic impedance measurement device 2405 in alternative embodiments.
  • FIG. 25 further illustrates the diuretic infusion device 5101. The diuretic infusion device 2501 has a needle 2503 and cannula 2502. The diuretic infusion device 2501 is connected to a human body 2511 subcutaneously via a cannula 2502. The diuretic infusion device 2501 is disposable in some embodiments, but the reservoir of the diuretic infusion device can alternatively be refilled via a hole 2505. The remote control device 2504 programs and controls the diuretic infusion device 2501. The remote control device 2504 contains a programmable processor, a controller, a wireless transmitter/receiver, a keypad with order entry buttons 2507, 2508, 2509, 2510 and a display screen 2506, though some embodiments may contain fewer components or additional components. Measured biological parameters shown in other figures can be transmitted wirelessly from a biological parameter measurement device to the remote control device 2404, 2504 in this embodiment. In alternative embodiments, a user manually inputs measured biological parameters into the remote control device 2504. A controller of the remote control device 2504 may be coupled to a processor and a wireless receiver/transmitter. When biological parameter information enters the processor of the remote control device 5104, the processor can compute the dosage of diuretic based on the biological parameter(s). The remote control device 2504 wirelessly transmits commands to the diuretic infusion device 2501. The remote control device 2504 can control the infusion rate of the diuretic infusion device 2501 wirelessly or by other means (e.g., wired). A user can choose and program particular diuretic infusion protocol(s) using button(s) 2507, 2508, 2509, 2510 on the keypad of the remote control device 2504. Various drug infusion protocols and methods shown in other figures (see FIGS. 14-15, 17-20, 23, 55 and other figures) may be embedded in the processor of the remote control device 2504. The processor within the remote control device 2504 may be able to compute the dosage of a diuretic based on the amount of salt, sodium and/or water of food. A user may infuse a diuretic before or when the user eats food that contains salt and/or water to excrete extra salt and water to maintain optimal body fluid condition. In other embodiments, the processor within the remote control device 2504 computes the dosage of diuretic based on various biological parameters using protocols shown in other figures. For example, FIGS. 36 and 37 show various biological parameters and factors that may be used in these embodiments. The biological parameter measurement sensors can be coupled with an implantable device(s) like a pacemaker, an implantable cardioverter defibrillator, a cardiac resynchronization therapy, etc. The remote control device 2504 can communicate wirelessly with the biological parameter measurement sensor(s). An intracardiac/intravascular pressure monitoring sensor, an intrathoracic impedance monitor sensor, or a patch sensor can communicate wirelessly with the remote control device 2504 in alternative embodiments.
  • FIG. 26 illustrates another embodiment of the present invention. In this embodiment, the diuretic infusion pump system can be a closed loop drug infusion system. The closed loop drug infusion system includes a biological parameter measurement sensor and/or a biological parameter measurement device, a controller, drug infusion pump, a drug delivery system, wireless communication module, though not all of these may be included in alternative embodiments or additional modules or devices may be included. In the closed loop drug infusion system, measured biological parameter signal enters the controller of the diuretic infusion system wirelessly or via other means. The controller of the diuretic infusion pump automatically adjusts and controls the drug infusion according to the algorithms programmed in the diuretic infusion pump in the closed loop drug infusion system. The controller of the diuretic infusion pump adjusts the drug infusion to achieve or maintain a target biological parameter which is programmed into the diuretic infusion pump.
  • As shown in FIG. 27, many different biological parameter measurement sensors and/or biological parameter measurement devices can be used for the present invention. Examples of these biological parameter measurement sensors/devices include, but are not limited to, a patch sensor system, an intracardiac pressure sensor system, an intravascular pressure sensor system, an intrathoracic impedance monitor sensor system, a non-invasive blood pressure measurement sensor system, a weight measurement sensor and/or device, a blood pressure measurement cuff and device, a heart rate measurement sensor system, an electrocardiogram monitoring sensor and/or device, an arrhythmia monitoring sensor system and other vital sign measurement devices. These biologic sensors can be coupled with other implantable medical devices, such as a pacemaker, an ICD, or a cardiac resynchronization therapy. The biological parameter measurement sensor/device and the diuretic infusion pump can preferably communicate wirelessly. The sensor/device and the diuretic infusion pump may communicate via other means in alternative embodiments. Other means may include, but are not limited to, wired communication, manual data input and other methods described in the present invention. More than one biological parameter sensor and/or device may be used in combination with a diuretic infusion pump. For example, a weight measurement device and intravascular blood pressure measurement sensor system may be used in combination with a diuretic infusion pump. A weight measurement device and a patch sensor may be used in combination with a diuretic infusion pump. These different sensors and devices may communicate wirelessly or via other means. Different types of patch sensors may be included in the closed and/or open loop drug infusion system. The patch sensor is further described in FIG. 28. The drug infusion system may adjust the infusion of drug(s) according to an average (e.g., a mean or median) value of biological parameters in alternative embodiments. For example, the drug infusion system can adjust the infusion of diuretics according to the average of the measured weight over three days. If the daily measured body weight is 70 kg, 72 kg, 71 kg over the past three days, the diuretic infusion pump can be programmed to adjust the rate of diuretic infusion according to 71 kg which is median value of three measured weights. The drug infusion system can adjust the infusion of diuretics according to the average value of measured intrathoracic electrical impedance over a period of time. In some embodiments, the diuretic infusion pump is programmed to adjust the rate of diuretic infusion according to an average value of biomarkers, blood pressure, intracardiac pressure or other biological parameters mentioned previously over a certain period of time.
  • In alternative embodiments, the diuretic infusion pump system is an open loop drug infusion system. The diuretic infusion pump can receive measured weight or other biological parameters from sensor(s) wirelessly or manually, however the diuretic infusion pump may or may not automatically adjust the rate of infusion in an open loop system. A user, a doctor, a nurse and/or other people that are involved in the use of the diuretic infusion pump system may need to approve or choose particular protocol(s) and methods. These people can also control the controller of the diuretic infusion pump. Healthcare provider(s) can transmit a new order or new drug infusion protocols to the diuretic infusion pump system via the Internet, a phone, or other methods. In an open loop drug infusion system, wireless communication among the devices may or may not be used.
  • In some embodiments, a user chooses an open loop system, a closed loop system, or mixed loop system (e.g., a closed loop system when a certain conditions are met and open loop system when a certain conditions are not met). The diuretic infusion pump system can be programmed to be a closed loop system when measured blood pressure is within a certain parameter, when a user does not have symptoms, such as chest pain, and/or when the dosage of an infused drug is within a certain range. The diuretic infusion pump can be programmed to be an open loop system when these conditions are not met in a mixed loop system.
  • FIG. 28 illustrates a patch sensor system 2802 and a drug infusion pump 2803. The patch sensor system 2802 is attached to a human body 2801. The patch sensor system can contain more than one sensor 2804, 2805 and/or electrodes 2804, 2805. The patch sensor system can be coupled to a processor, wireless communication module, a controller and software program, though it may not be coupled to all of these in alternative embodiments or may be coupled to additional devices. In some embodiments, the patch sensor system 2802 measures blood pressure, heart rate, intrathoracic electrical impedance, body fluid status, heart rhythm, biomarkers, and detects heart arrhythmia. This patch sensor 2802 is preferably attached to the chest, but may be attached to back, head or other parts of the body in alternative embodiments. The patch sensor 2802 can include an electrode generating an electrical waveform and/or an optical system generating an optical waveform to measure various biological parameters, such as blood pressure, pulse, oxygen saturation, heart rhythm. Intrathoracic electrical impedance can be measured by the patch sensor system 2802 using multiple electrodes and/or multiple sensors. Intrathoracic impedance between multiple sensors and electrodes can be measured multiple times a day in one embodiment. The patch sensor system 2802 communicates wirelessly with the diuretic infusion pump 2803 in a closed loop drug infusion system or an open loop drug infusion system. The diuretic infusion pump 2803 adjusts the infusion of diuretics and/or other drugs according to biological parameter(s) measured by the patch sensor system 2802 to maintain the target biological parameter. The diuretic infusion pump can adjust the infusion of diuretics and/or other drug(s) to maintain, for example, target blood pressure, intrathoracic impedance, heart rate, body fluid condition surrogate marker, etc., using drug infusion protocols shown in other figures. More than one patch sensor system 2802 can be used and attached to different parts of the body. One example of a suitable external patch sensor monitoring system is MUSE™ clinical system from CORVENTIS™, INC.
  • FIG. 29 illustrates another example of a drug infusion protocol. In one example, the measured intracardiac pressure of a user is 17 mmHg and the target intracardiac pressure is set at 12 mmHg. There is 5 mmHg difference between the target cardiac pressure and measured cardiac pressure, and the measured cardiac pressure is above the target cardiac pressure. Following the protocol seen in FIG. 29, the basal rate of furosemide infusion increases by 0.3 mg multiplied by 5 and 0.3 mg multiplied by 5 is equal to 1.5 mg. The basal rate of furosemide infusion increases by 1.5 mg per hour for 8 hours following the protocol. If the previously set basal rate of furosemide was 1 mg per hour for 8 hours daily, the new basal rate of the furosemide is 2.5 mg per hour for 8 hours daily. A user or a healthcare provider can change the underlined numbers according to a person's sensitivity to diuretics. The change of the protocol could occur automatically or occur upon the approval of a user and/or healthcare provider(s).
  • FIG. 30 illustrates wireless communication between a diuretic pen 3001 and a remote control device 3002 which receives biological parameter information from biological parameter measurement device. Measured biological parameter may be input into the diuretic pen wirelessly or manually. A user may input biological parameter manually by using button(s), a knob, etc. As shown in FIG. 31, the diuretic pen 3001 can contain a processor, software, and telemetry system, though the diuretic pen may not have all of these components or may have additional components. The processor within the diuretic pen can compute the dose of diuretic drug based on the biological parameter.
  • FIG. 32 illustrates examples of sensors/devices measuring various biological parameters. These devices and/or sensors are connected to a diuretic pen wirelessly in some embodiments. The diuretic pen can compute the dose of diuretic injection based on these biological parameters.
  • FIG. 33 shows possible data flow for computation of the diuretics dose. In alternative embodiments, the processor uses various other factors to compute diuretics dose. Examples include physical signs, vital signs, bio markers, symptoms, intracardiac pressure, intravascular pressure, intrathoracic electrical impedance and NYHA classification, etc., as shown in FIG. 33. For example, if B-type natriuretic peptide (BNP) is elevated, this may indicate increased body fluid volume and congestive heart failure. If BNP is above 100 pg/ml, the diuretic pen can increase (or adjust) the dose of the diuretics.
  • FIG. 34 illustrates another embodiment of the present invention. This figure shows another type of a drug dispensing apparatus. One embodiment of this drug dispensing apparatus is a pen-type apparatus 3406 which contains medication pills 3404. Some embodiments of this pen-type apparatus contain drug suspension. For example, a user may use this pen-type drug dispensing apparatus 3406 based on “sodium counting.” “Sodium counting” is utilized when a user or a processor of a device calculates the dosage of diuretic based on the amount of sodium intake. For example, a user may be instructed by a physician to use 2 mg of furosemide per 50 mg of sodium intake. The pen-type apparatus might contain multiple 2 mg or 1 mg furosemide pills, though various doses of furosemide can be contained in the apparatus. If a user plans to eat 350 mg of sodium, the user can take 14 mg of furosemide according to the “sodium counting.” Thus, 14 mg can be input into the pen-type apparatus using a button 3407 and a knob 3401. When knob 3401 is pushed, screw 3403 is moved to push the pills out of the drug container. Screw 3403 movement is controlled by a processor in some embodiments, though screw 3403 movement is controlled manually in other embodiments. The dosage of 14 mg furosemide is not readily available at a pharmacy because 14 mg is not a commonly used dose of furosemide pill. If the pen-type apparatus contains 2 mg furosemide pills, 7 furosemide tablets are taken out of the dispenser. This pen-type drug dispensing apparatus makes it easy to dispense various doses of diuretics and other medications. In one embodiment, this pen-type diuretic dispensing apparatus contains a processor which can compute the dose of diuretics when a user inputs the amount of sodium or salt into the pen-type diuretic dispensing apparatus. A user can input the amount of sodium or salt using knob 3401 and/or buttons on the apparatus. In alternative embodiments, when knob 3401 is pressed, a predetermined number of pills are released out of the container 3406. For example, two tablets of 1 mg furosemide pill can be released out of the container when knob 3401 is pressed. The user may be instructed to press the knob 3401 one time when the user plans to eat food with low salt and/or water content, to press the knob 3401 twice when a user plans to eat food with moderate salt and/or water content, or press the knob 3401 three times when he plans to eat food with high salt and/water content.
  • FIG. 35 illustrates another embodiment of the invention. In this embodiment, a disposable external diuretic infusion pump 3501 is attached to the body 3505 of a user. This disposable external diuretic infusion pump includes a reservoir that contains the diuretic. This external diuretic infusion pump 3501 can be a metered dose infusion pump. The external diuretic infusion pump 3501 is set to deliver a predetermined volume of a drug to the user. When the user pushes a button 3502, a predetermined volume of the drug is delivered via a cannula 3503 to the user. The tip of the cannula 3503 is located subcutaneously in a preferred embodiment. In some embodiments, a reservoir may be refilled through a hole 3504. One example of a metered dose diuretic infusion is as follows. If a user is expected to eat food that contains salt, the user may be instructed to use this metered dose diuretic infusion pump before or at the time of eating this food. For example, a pump may deliver 1 mg of furosemide to the user each time button 3502 is pressed. The user can be instructed to press the button 3502 one time when the user plans to eat food with low salt content, twice when the user plans to eat food with moderate salt content, three times when the user plans to eat food with high salt content. The user may be able to urinate and excrete salt shortly after eating using this device system. People with heart failure are instructed to avoid food with high salt content because of body salt and fluid overload. This apparatus and method can allow people to take an extra amount of salt/water and still prevent them from developing salt/body fluid overload. The metered dose diuretic infusion pump can deliver a diuretic based on measured body weight. The user may be instructed to press the button 3502 once when the measured body weight is 1 kg above target weight, twice when the measured body weight is 1-2 kg above target weight, and three times when the measured body weight is more than 2 kg above target weight. The metered dose drug infusion pump can be implanted under skin in some embodiments.
  • FIG. 36 illustrates another embodiment. It can be important to measure body weight and/or biological parameters regularly, to take electrolyte supplements, such as potassium supplement or magnesium supplement, and to measure blood pressure while a user uses a diuretic infusion pump for safety reasons. As shown in FIG. 36, the user is asked if he took potassium supplement, measured his body weight, and measured his blood pressure. If the user inputs “yes,” the diuretic infusion pump is programmed to continue diuretic infusion. If the user inputs “no,” the diuretic infusion pump can be programmed to discontinue diuretic infusion until the user inputs “yes.” This feedback mechanism is a safety feature of the diuretic infusion system.
  • FIG. 37 illustrates examples of sensors/devices measuring various biological parameters. These devices and/or sensors are connected to a remote control device wirelessly in some embodiments. The remote control device can compute the dose of diuretic injection based on these biological parameters.
  • FIG. 38 shows possible data flow for computation of the diuretics dose. In alternative embodiments, the processor uses various other factors to compute diuretics dose. Examples include physical signs, vital signs, bio markers, symptoms, intracardiac pressure, intravascular pressure, intrathoracic electrical impedance and NYHA classification, etc. For example, if B-type natriuretic peptide (BNP) is elevated, this may indicate increased body fluid volume and congestive heart failure. If BNP is above 100 pg/ml, the remote control device can compute the dosage and increase (or adjust) the dose of the diuretics.
  • A photograph of the user's legs or other parts of the body can be taken by the diuretic infusion pump system by a camera or a cell phone. The photograph can be transmitted to a healthcare provider. The healthcare provider reviews the photograph of legs, and may be able to verify the body fluid condition by comparing the measured weight with the photograph. The diuretic infusion pump can also have a built-in camera. The healthcare provider can detect malfunction of the weight scale when the measured body weight is far greater than the target weight but the photograph of the legs does not show any swelling.
  • FIG. 39 illustrates another embodiment of the invention. Urinary catheter 3905 is placed into a bladder of a human body 3902. Urinary catheter 3905 is connected with a drainage bag 3904. The amount of urine output over a period of time can be measured using this urinary catheter and drainage bag. In one embodiment, the urine output measurement system can include a urinary catheter, a drainage bag, a sensor to measure urine output, a transmitter, a receiver, a processor, software, etc., though it can have fewer or more components. The measured urine output over a predetermined period of time is transmitted wirelessly or by other means (e.g., wired, manual data input, etc.) to a diuretic infusion pump 3901. The diuretic infusion pump 3901 automatically adjusts the infusion rate of diuretic based on the urine output in order to achieve a target urine output. In alternative embodiments, the diuretic infusion pump has a separate a remote control device, a portable computer system, a PDA, etc., which can communicate wirelessly or via other means (e.g., wired, manual data input, etc.) with the urine output measurement system.
  • As one example, a physician programs the diuretic infusion pump system to achieve 2400 ml of urine output over a 24-hour period. In order to achieve this, a urine output of 100 ml per hour is required on average over 24 hours. Various diuretic infusion protocols shown in other figures may be programmed into the diuretic infusion pump. The sensor of the urine output measurement system measures the amount of the urine output. The transmitter of the urine output measurement system transmits the urine output information wirelessly or by other means (e.g., wired, manual data input, etc.) to the diuretic infusion pump system and/or a separate computer, a remote control device, etc. If the urine output over a predetermined period of time is less than the target urine output, the diuretic infusion pump can increase diuretic infusion to increase urine output. If the urine output over a predetermined period of time is greater than the target urine output, the diuretic infusion pump can decrease diuretic infusion to decrease urine output. If the urine output were 80 ml over one hour, the diuretic infusion pump would increase the diuretic infusion to achieve 120 ml over the next hour to achieve 100 ml per hour of urine output. The diuretic infusion pump 3901 can deliver the diuretic intravascularly, subcutaneously, intramuscularly, etc. In one embodiment, the diuretic infusion pump 3901 can communicate wirelessly or by other means (e.g., wired, manual data input, etc.) with a non-invasive blood pressure monitoring system 3907. The non-invasive blood pressure monitoring system 3907 can have a processor, a controller, software, a wireless transmitter/receiver, though it may have fewer or more components in alternative embodiments.
  • When blood pressure is measured using a blood pressure cuff 3906, the measured blood pressure is transmitted wirelessly or by other means (e.g., wired, manual data input, etc.) to the diuretic infusion pump 3901. If blood pressure is below a predetermined level, the diuretic infusion pump 3901 can stop the diuretic infusion or adjust the diuretic infusion based on the program. This system may reduce the risk of hypotension. If blood pressure is above a predetermined level, the diuretic infusion pump 3901 can increase diuretic infusion or adjust the diuretic infusion based on the program.
  • In alternative embodiments, the urine output measurement system comprises a urinary catheter, a urine drainage bag, and a sensor to measure urine output, but does not include a wireless transmitter and receiver. The user may input the urine output over a certain period of time manually into a diuretic infusion pump system and/or a separate computer or a remote control device. In alternative embodiments, the diuretic infusion pump system can communicate wirelessly or by other means (e.g., wired, manual data input, etc.) with the urine output measurement system and other biological parameter sensors (see other figures). The diuretic infusion pump system can adjust the diuretic infusion to maintain the target urine output, as well as to maintain the target biological parameter (e.g., the target intravascular pressure, the target intracardiac pressure, and/or the target intrathoracic impedance).
  • FIG. 40 illustrates the operation of a diuretic infusion system according to one embodiment. In FIG. 40, the urine output measurement sensor and processor are onboard, within a housing of the urine output measurement apparatus. The urine output measurement sensor is electrically connected to the processor, and sends the measured urine output to the processor. The processor is connected to a telemetry system and a signal transmitter. The urine output information is sent from the telemetry system of the urine output measurement apparatus via the transmitter.
  • The urine output information signal is received by a receiver of the diuretic infusion pump. The receiver of the diuretic infusion pump is electrically connected to a processor which is housed in the diuretic infusion pump. The processor receives the urine output information and performs computations to determine the diuretic infusion rate, such as basal rate and bolus rate, according to programmed parameters, protocols and algorithms. The processor controls an electric motor to deliver diuretic from a reservoir to a user through an outlet, a tube, and an infusion set of the diuretic infusion pump. In alternative embodiments, the user manually inputs measured urine output into the diuretic infusion device. This urine output information enters a processor which is housed in the diuretic infusion pump. The processor performs computations to determine the diuretic infusion rate as described with regard to other figures.
  • FIG. 41 illustrates the wireless operation of the diuretic infusion pump system. The urine output measurement system 4101 includes a urine output measurement sensor 4102, a processor 4103, and a wireless transmitter 4104 (or a wireless receiver), a urinary catheter, a urine drainage apparatus, and an antenna 4105. The transmitter 4104 sends signals 4106 that contain urine output information.
  • The urine output signal(s) can be sent to different receivers. The diuretic infusion pump receives the signal(s) 4106 through an onboard receiver 4108 via an antenna 4107. A handheld communication device, such as a remote control device, an iPOD™, an MP3 player, a handheld computer, or a portable phone may receive the signal 4106 through an onboard receiver 4112 via an antenna 4111. The user may choose to send information to a computer or handheld communication device for the purpose of saving urine output information on the computer or connecting with the Internet to send urine output information to healthcare providers. The diuretic infusion pump system and/or handheld communication device can receive biological parameter signal(s) wirelessly or by other means (e.g., wired, manual data input, etc.) from the biological parameter sensor, transmitter, or processor 4110. FIG. 38 provides examples of biological parameters.
  • FIG. 42 illustrates an example of furosemide infusion protocol based on urine output.
  • FIG. 43 illustrates an ambulatory diuretic infusion pump 4301 mounted at a pole 4310. A diuretic contained in a bag 4303 is infused into a vein of a patient 4305 through an intravenous tube system 4304. The diuretic infusion pump 4301 contains a controller which adjusts the rate of diuretic infusion based on urine output and/or other biological parameter(s). A user can input the urine output measured by urine output measurement system 4308, 4309 using a keypad 4302 or using a remote controller. The urine output measured by the urine output measurement system can be transmitted wirelessly to the diuretic infusion pump 4301 in another embodiment. The blood pressure measured by blood pressure measurement system 4306, 4307 can be manually input into the diuretic infusion pump 4301 or transmitted wirelessly into the diuretic infusion pump 4301.
  • FIG. 44 illustrates an ambulatory diuretic infusion pump 4401 mounted at a pole 4402. A diuretic contained in a bag 4406 is infused into a vein of a patient 4404 through intravenous tube system 4403. The diuretic infusion pump 4401 contains a controller which adjusts the rate of diuretic infusion based on weight and/or other biological parameters. A user can input the weight measured by weight measurement scale 4405 into the diuretic infusion pump 4401 using a keypad. 4407 or using a remote control device. The weight measured by the scale 4405 can be transmitted wirelessly to the diuretic infusion pump in another embodiment.
  • Even though the term “diuretic infusion pump” (or “diuretic infusion system” or similar variants) is used in this application, one of ordinary skill in the art would know that this term is not limited to the use of diuretics, but can also use other types of drugs, as well. Thus, this term is not limited to diuretics. Many different drugs can be used for the diuretic infusion pump. Examples of such drugs are described in other parts of the application.
  • Diuretic infusion pumps can contain two reservoirs in some embodiments. One reservoir can contain furosemide. The other reservoir can contain buffering solution. Buffering solution includes (but is not limited to) sodium chloride solution, Lactated Ringer's solution, or Dextrose 5% solution. Some furosemide solution may have a high pH of about 9. Mixing a furosemide solution with a sodium chloride solution, Lactated Ringer's solution or Dextrose 5% solution may lower the pH of the furosemide solution.
  • Furosemide discolors when it is exposed to light. Discolored furosemide is not recommended to be used. A reservoir and cartridge within a diuretic infusion pump may be light resistant to protect furosemide or other drugs from being exposed to the light.
  • In all of the above embodiments, the diuretic infusion pump was located external to the body. However, alternatively, internal and implantable diuretic infusion pumps may also be made. The diuretic infusion pumps are also shown as portable in the above description. In alternative embodiments, the diuretic infusion pump may not be portable.
  • In another aspect of the invention, a user of the diuretic infusion pump may choose to use the device for long term or may choose to use it for short term when his body weight changes. The diuretic infusion pump can also be used in various locations: home, outpatient facilities and hospitals, as well as the intensive care unit.
  • Programs and protocols coupled with the diuretic infusion pump preferably have various safety measures to minimize side effects of diuretics. One example of a safety measure is that the diuretic infusion pump stops infusing diuretics when a user does not measure body weight in a certain period after previous weight measurements. For example, the diuretic infusion pump may be programmed to stop diuretic infusion in two days if the diuretic infusion pump does not receive a new body weight measurement. This safety measure helps to avoid using inappropriately high dose of diuretics when previously measured body weight is higher than actual body weight. Alarms and display on the screen may be programmed to request a user to enter a new body weight measurement into the diuretic infusion pump.
  • The above description and illustration of preferred embodiments of the invention has been presented to provide illustration and description. It is not intended to limit the invention to the precise forms that are disclosed. Many variations and modifications will be apparent to people skilled in this art.
  • Depending on the form of the components, “coupling” or “connection” between components may take different forms. Dedicated circuitry can be coupled to each other by hardwiring or by accessing a common register or memory location, for example. Software “coupling” can occur by any number of ways to pass information between software components (or between software and hardware, if that is the case). The term “coupling” is meant to include all of these and is not meant to be limited to a hardwired permanent connection between two components. In addition, there may be intervening elements. For example, when two elements are described as being coupled to each other, this does not imply that the elements are directly coupled to each other nor does it preclude the use of other elements between the two.

Claims (20)

1. A diuretic infusion system comprising:
a biological parameter measurement apparatus including:
a biological parameter measurement sensor for measuring a biological parameter of a human patient; and
a diuretic infusion device including:
a reservoir for holding a diuretic;
a pump connected to the reservoir and connectable to the human patient, for infusing diuretic from the reservoir into the human patient; and
a controller for controlling the pump and rate of infusion of the diuretic based on the measured biological parameter.
2. The system of claim 1, wherein:
the biological parameter measurement apparatus further includes a wireless transmitter for wirelessly transmitting measured biological information; and
the diuretic infusion device further includes a wireless receiver for wirelessly receiving the biological parameter information transmitted by the biological parameter measurement apparatus, the controller controlling the pump and rate of infusion of the diuretic based on the received biological parameter information.
3. The system of claim 1, wherein the biological parameter measurement sensor is a patch sensor.
4. The system of claim 1, wherein the biological parameter measurement sensor is an intracardiac pressure measurement sensor and the controller adjusts the rate of infusion based on a measured pressure within a cardiac chamber of the patient.
5. The system of claim 4, wherein the controller adjusts the rate of infusion based on the measured pressure within the cardiac chamber to maintain a target pressure in the cardiac chamber.
6. The system of claim 1, wherein the biological parameter measurement sensor is an intravascular pressure measurement sensor and the controller adjusts the rate of infusion based on a measured pressure within a blood vessel of the patient.
7. The system of claim 6, wherein the controller adjusts the rate of infusion based on the measured pressure within the blood vessel to maintain a target pressure in the blood vessel.
8. The system of claim 1, wherein the biological parameter measurement sensor is an intrathoracic electrical impedance measurement sensor and the controller adjusts the rate of infusion based on a measured intrathoracic electrical impedance.
9. The system of claim 1, wherein the biological parameter measurement apparatus is a non-invasive blood pressure measurement device. and the controller adjusts the rate of infusion based on a measured blood pressure of the patient
10. The system of claim 1 wherein the biological parameter measurement apparatus is coupled to a pacemaker.
11. The system of claim 1 wherein the biological parameter measurement apparatus is coupled to an implantable cardioverter defibrillator.
12. The system of claim 1 wherein the biological parameter measurement apparatus is coupled to a cardiac resynchronization therapy.
13. The system of claim 1, wherein the biological parameter is a biomarket and the controller adjusts the rate of infusion based on the measured biomarker.
14. The system of claim 13, wherein the biomarker is selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, and a NT-pro brain natriuretic peptide.
15. The system of claim 1, wherein the system is further configured for administering a drug selected from a group consisting of: ACE inhibitor, calcium channel blocker, beta blocker, inotropic agent, hydralazine, loop diuretics, thiazide diuretics, and vasopressin receptor antagonist
16. The system of claim 1, wherein the pump is a portable pump.
17. The system of claim 1, wherein the pump is a non-portable pump.
18. The system of claim 1, wherein the pump is an ambulatory drug infusion pump.
19. The system of claim 1, wherein the pump is an implantable drug infusion pump.
20. A method for infusing diuretic to a human patient comprising:
receiving non-weight biological parameter information based on measurements of a non-weight biological parameter for a patient; and
adjusting an infusion rate of diuretic into the patient based on the measured non-weight biological parameter according to a predetermined protocol.
US12/202,094 2007-09-01 2008-08-29 Control of body fluid condition using diuretics, based on biological parameters Abandoned US20090062730A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/202,094 US20090062730A1 (en) 2007-09-01 2008-08-29 Control of body fluid condition using diuretics, based on biological parameters

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US96702507P 2007-09-01 2007-09-01
US97963407P 2007-10-12 2007-10-12
US98697407P 2007-11-09 2007-11-09
US98837507P 2007-11-15 2007-11-15
US4811308P 2008-04-25 2008-04-25
US12/202,094 US20090062730A1 (en) 2007-09-01 2008-08-29 Control of body fluid condition using diuretics, based on biological parameters

Publications (1)

Publication Number Publication Date
US20090062730A1 true US20090062730A1 (en) 2009-03-05

Family

ID=40387869

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/202,068 Abandoned US20090062728A1 (en) 2007-09-01 2008-08-29 Control of Body Fluid Condition Using Diuretics, Based on Weight Measurement
US12/202,089 Abandoned US20090062729A1 (en) 2007-09-01 2008-08-29 Controlling body fluid condition using diuretics
US12/202,072 Expired - Fee Related US8070742B2 (en) 2007-09-01 2008-08-29 Method for controlling body fluid condition using diuretics, based on weight measurement
US12/202,094 Abandoned US20090062730A1 (en) 2007-09-01 2008-08-29 Control of body fluid condition using diuretics, based on biological parameters

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US12/202,068 Abandoned US20090062728A1 (en) 2007-09-01 2008-08-29 Control of Body Fluid Condition Using Diuretics, Based on Weight Measurement
US12/202,089 Abandoned US20090062729A1 (en) 2007-09-01 2008-08-29 Controlling body fluid condition using diuretics
US12/202,072 Expired - Fee Related US8070742B2 (en) 2007-09-01 2008-08-29 Method for controlling body fluid condition using diuretics, based on weight measurement

Country Status (2)

Country Link
US (4) US20090062728A1 (en)
WO (1) WO2009029899A1 (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107568A1 (en) 2010-03-05 2011-09-09 B. Braun Melsungen Ag System and method for administering medicaments on the basis of urine values
WO2011126485A1 (en) * 2010-04-08 2011-10-13 Cardiac Protection Solutions, Llc Method and apparatus for delivering continuous intravenous infusion of metoprolol
US20120035432A1 (en) * 2010-08-03 2012-02-09 Rodolphe Katra Medical device and methods of monitoring a patient with renal dysfunction
US8234126B1 (en) * 2008-02-12 2012-07-31 Asante Solutions, Inc. Distribution of infusion pumps
US20120238960A1 (en) * 2009-07-07 2012-09-20 Sanofi-Aventis Deutschland Gmbh Drug delivery device and set of a drug delivery device and a plurality of mountable elements
US20120253288A1 (en) * 2009-08-27 2012-10-04 Sanofi-Aventis Deutschland Gmbh Reminder device for drug delivery devices
US20120259285A1 (en) * 2009-09-23 2012-10-11 Sanofi-Aventis Deutschland Gmbh Assembly for a drug delivery device and drug delivery device
US8295918B2 (en) 2011-02-25 2012-10-23 Pacesetter, Inc. Systems and methods for activating and controlling impedance-based detection systems of implantable medical devices
US20130016105A1 (en) * 2009-12-02 2013-01-17 Sanofi-Aventis Deutschland Gmbh Dose display mechanism for a drug delivery device
US8380303B2 (en) 2011-02-25 2013-02-19 Pacesetter, Inc. Systems and methods for activating and controlling impedance-based detection systems of implantable medical devices
CN103209639A (en) * 2010-10-15 2013-07-17 费森尤斯医疗保健控股有限公司 Dry weight predictor
WO2013154784A1 (en) * 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
WO2013154783A1 (en) * 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
WO2014138796A1 (en) * 2013-03-15 2014-09-18 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
US8868185B2 (en) 2011-10-31 2014-10-21 Medtronic, Inc. Use of thoracic and extra-thoracic impedance for diagnostic monitoring
US20150127738A1 (en) * 2013-11-05 2015-05-07 Proteus Digital Health, Inc. Bio-language based communication system
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
US9597010B2 (en) 2005-04-28 2017-03-21 Proteus Digital Health, Inc. Communication system using an implantable device
US9597511B2 (en) 2011-10-31 2017-03-21 Medtronic, Inc. Method to assess hemodynamic performance during cardiac resynchronization therapy optimization using admittance waveforms and derivatives
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
WO2017054006A1 (en) 2015-09-25 2017-03-30 Sanmina Corporation System and method for a drug delivery and biosensor patch
US9616107B2 (en) 2011-02-25 2017-04-11 Capricor Therapeutics, Inc. Therapy for kidney disease and/or heart failure
US9623085B2 (en) 2011-09-02 2017-04-18 Capricor Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9787511B2 (en) 2013-09-20 2017-10-10 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9941931B2 (en) 2009-11-04 2018-04-10 Proteus Digital Health, Inc. System for supply chain management
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US10004754B2 (en) 2014-03-14 2018-06-26 Madeleine Pharmaceuticals Pty Ltd. ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10086138B1 (en) * 2014-01-28 2018-10-02 Masimo Corporation Autonomous drug delivery system
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US10238604B2 (en) 2006-10-25 2019-03-26 Proteus Digital Health, Inc. Controlled activation ingestible identifier
WO2019141575A1 (en) * 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Assistance in the treatment of cardiac insufficiency
US10362968B2 (en) 2010-10-15 2019-07-30 Fresenius Medical Care Holdings, Inc. Bioimpedance circumference measurement
US10368774B2 (en) 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
US10376218B2 (en) 2010-02-01 2019-08-13 Proteus Digital Health, Inc. Data gathering system
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US10441194B2 (en) 2007-02-01 2019-10-15 Proteus Digital Heal Th, Inc. Ingestible event marker systems
US10517506B2 (en) 2007-05-24 2019-12-31 Proteus Digital Health, Inc. Low profile antenna for in body device
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US10744262B2 (en) 2015-07-19 2020-08-18 Sanmina Corporation System and method for health monitoring by an ear piece
US10881774B2 (en) 2016-09-23 2021-01-05 Plc Medical Systems, Inc. Method and system to protect kidneys during surgery
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US20210236727A1 (en) * 2018-05-18 2021-08-05 Reprieve Cardiovascular, Inc. Method and system to treat acute decompensated heart failure
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US11259745B2 (en) 2014-01-28 2022-03-01 Masimo Corporation Autonomous drug delivery system
US11357446B2 (en) * 2019-12-06 2022-06-14 Reprieve Cardiovascular, Inc. Managing fluid levels in a patient and associated devices, systems, and methods
US11464423B2 (en) 2007-02-14 2022-10-11 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
WO2022259115A1 (en) * 2021-06-10 2022-12-15 Terumo Kabushiki Kaisha Closed-loop home diuretic therapy system
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11571515B2 (en) 2019-08-29 2023-02-07 Medtronic Minimed, Inc. Controlling medical device operation and features based on detected patient sleeping status
US11642078B2 (en) * 2019-12-05 2023-05-09 Medtronic, Inc. Intervention for heart failure management
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US11887712B2 (en) 2019-12-13 2024-01-30 Medtronic Minimed, Inc. Method and system for classifying detected events as labeled event combinations for processing at a client application
US11928614B2 (en) 2006-05-02 2024-03-12 Otsuka Pharmaceutical Co., Ltd. Patient customized therapeutic regimens

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9427520B2 (en) 2005-02-11 2016-08-30 Carefusion 303, Inc. Management of pending medication orders
US10353856B2 (en) 2011-03-17 2019-07-16 Carefusion 303, Inc. Scalable communication system
US11087873B2 (en) 2000-05-18 2021-08-10 Carefusion 303, Inc. Context-aware healthcare notification system
US20080172026A1 (en) 2006-10-17 2008-07-17 Blomquist Michael L Insulin pump having a suspension bolus
US8361026B2 (en) 2005-02-01 2013-01-29 Intelliject, Inc. Apparatus and methods for self-administration of vaccines and other medicaments
US8231573B2 (en) 2005-02-01 2012-07-31 Intelliject, Inc. Medicament delivery device having an electronic circuit system
US9022980B2 (en) 2005-02-01 2015-05-05 Kaleo, Inc. Medical injector simulation device
PL2058020T3 (en) 2005-02-01 2013-03-29 Kaleo Inc Devices for medicament delivery
US8206360B2 (en) 2005-02-01 2012-06-26 Intelliject, Inc. Devices, systems and methods for medicament delivery
WO2008091838A2 (en) 2007-01-22 2008-07-31 Intelliject, Inc. Medical injector with compliance tracking and monitoring
US8021344B2 (en) 2008-07-28 2011-09-20 Intelliject, Inc. Medicament delivery device configured to produce an audible output
USD994111S1 (en) 2008-05-12 2023-08-01 Kaleo, Inc. Medicament delivery device cover
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
EP2525710B1 (en) * 2010-01-22 2014-08-06 Lifescan, Inc. Analyte testing method and system
US11344460B1 (en) 2011-09-19 2022-05-31 Dp Technologies, Inc. Sleep quality optimization using a controlled sleep surface
US8382703B1 (en) * 2011-10-18 2013-02-26 King Saud University Piezoelectric dual-syringe insulin pump
CN102500016A (en) * 2011-11-03 2012-06-20 广州曼翔医疗器械有限公司 Medical analgesia pump wireless control device
AU2013249405B2 (en) 2012-04-20 2017-06-22 Smiths Medical Asd, Inc. Medication dispensers
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9238100B2 (en) 2012-06-07 2016-01-19 Tandem Diabetes Care, Inc. Device and method for training users of ambulatory medical devices
SE537225C2 (en) 2012-08-23 2015-03-10 Careligo Ab Patient monitoring device comprising drug titration and training modules
WO2014106096A1 (en) 2012-12-27 2014-07-03 Kaleo, Inc. Devices, systems and methods for locating and interacting with medicament delivery systems
US10086141B2 (en) * 2013-01-29 2018-10-02 Sanofi-Aventis Deutschland Gmbh Electronic module and drug delivery device
WO2014159280A1 (en) * 2013-03-13 2014-10-02 Carefusion 303, Inc. Patient-specific medication management system
EP2973370A4 (en) 2013-03-13 2016-08-17 Carefusion 303 Inc Predictive medication safety
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
EP4250313A3 (en) 2013-12-26 2023-11-22 Tandem Diabetes Care, Inc. Integration of infusion pump with remote electronic device
US10279105B2 (en) 2013-12-26 2019-05-07 Tandem Diabetes Care, Inc. System and method for modifying medicament delivery parameters after a site change
US9721409B2 (en) * 2014-05-02 2017-08-01 Qualcomm Incorporated Biometrics for user identification in mobile health systems
US10492141B2 (en) * 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
AU2018210313A1 (en) 2017-01-17 2019-06-20 Kaleo, Inc. Medicament delivery devices with wireless connectivity and event detection
WO2018226991A1 (en) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
WO2019094963A1 (en) 2017-11-13 2019-05-16 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
CN112004563A (en) 2018-02-01 2020-11-27 施菲姆德控股有限责任公司 Intravascular blood pump and methods of use and manufacture
US11929160B2 (en) 2018-07-16 2024-03-12 Kaleo, Inc. Medicament delivery devices with wireless connectivity and compliance detection
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4034192A4 (en) 2019-09-25 2023-11-29 Shifamed Holdings, LLC Intravascular blood pump systems and methods of use and control thereof
US20220088305A1 (en) * 2020-09-21 2022-03-24 Icu Medical, Inc. Infusion pump with patient weight check
WO2023141237A1 (en) * 2022-01-20 2023-07-27 Cell and Molecular Tissue Engineering, LLC Methods and products to detect, minimize and treat trap-related tissue reactions and tissue injury associated with medical devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562001B2 (en) * 2000-01-21 2003-05-13 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US6970742B2 (en) * 2000-01-11 2005-11-29 Savacor, Inc. Method for detecting, diagnosing, and treating cardiovascular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109842A (en) * 1990-09-24 1992-05-05 Siemens Pacesetter, Inc. Implantable tachyarrhythmia control system having a patch electrode with an integrated cardiac activity system
EP0773805A1 (en) * 1993-02-18 1997-05-21 Baxter International Inc. Apheresis system incorporating alternative site for anticoagulant addition
US5395340A (en) * 1993-03-15 1995-03-07 Lee; Tzium-Shou Infusion pump and a method for infusing patients using same
US5616126A (en) * 1995-03-03 1997-04-01 Malekmehr; Farshad Low residual bladder catheter
US5984893A (en) * 1997-03-27 1999-11-16 Ward; Roger T. Blood infusion control system
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
DE20209051U1 (en) * 2001-12-21 2003-04-24 Disetronic Licensing Ag Medicament administration device has dosage adjuster mounted on piston rod and end stop mounted at end of its path, locking system preventing adjuster from rotating and pressing against stop
US7048141B2 (en) * 2002-05-14 2006-05-23 Antioch Holdings, Inc. Personal medication dispenser
US7986994B2 (en) * 2002-12-04 2011-07-26 Medtronic, Inc. Method and apparatus for detecting change in intrathoracic electrical impedance
GB0329288D0 (en) * 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
US7232435B2 (en) * 2004-02-06 2007-06-19 Medtronic, Inc. Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure
US7938817B2 (en) * 2004-09-09 2011-05-10 Plc Medical Systems, Inc. Patient hydration system and method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6970742B2 (en) * 2000-01-11 2005-11-29 Savacor, Inc. Method for detecting, diagnosing, and treating cardiovascular disease
US6562001B2 (en) * 2000-01-21 2003-05-13 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610128B2 (en) 2005-04-28 2020-04-07 Proteus Digital Health, Inc. Pharma-informatics system
US11476952B2 (en) 2005-04-28 2022-10-18 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US9681842B2 (en) 2005-04-28 2017-06-20 Proteus Digital Health, Inc. Pharma-informatics system
US9597010B2 (en) 2005-04-28 2017-03-21 Proteus Digital Health, Inc. Communication system using an implantable device
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
US10517507B2 (en) 2005-04-28 2019-12-31 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US10542909B2 (en) 2005-04-28 2020-01-28 Proteus Digital Health, Inc. Communication system with partial power source
US11928614B2 (en) 2006-05-02 2024-03-12 Otsuka Pharmaceutical Co., Ltd. Patient customized therapeutic regimens
US10238604B2 (en) 2006-10-25 2019-03-26 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US11357730B2 (en) 2006-10-25 2022-06-14 Otsuka Pharmaceutical Co., Ltd. Controlled activation ingestible identifier
US10441194B2 (en) 2007-02-01 2019-10-15 Proteus Digital Heal Th, Inc. Ingestible event marker systems
US11464423B2 (en) 2007-02-14 2022-10-11 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
US10517506B2 (en) 2007-05-24 2019-12-31 Proteus Digital Health, Inc. Low profile antenna for in body device
US11386482B2 (en) 2008-02-12 2022-07-12 Bigfoot Biomedical, Inc. Distribution of infusion pumps
US8543418B1 (en) * 2008-02-12 2013-09-24 Asante Solutions, Inc. Distribution of infusion pumps
US9141765B2 (en) 2008-02-12 2015-09-22 Bigfoot Biomedical, Inc. Distribution of infusion pumps
US8234126B1 (en) * 2008-02-12 2012-07-31 Asante Solutions, Inc. Distribution of infusion pumps
US10152742B2 (en) 2008-02-12 2018-12-11 Bigfoot Biomedical, Inc. Distribution of infusion pumps
US10636077B2 (en) 2008-02-12 2020-04-28 Bigfoot Biomedical, Inc. Distribution of infusion pumps
US10682071B2 (en) 2008-07-08 2020-06-16 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US11217342B2 (en) 2008-07-08 2022-01-04 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker data framework
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US20120238960A1 (en) * 2009-07-07 2012-09-20 Sanofi-Aventis Deutschland Gmbh Drug delivery device and set of a drug delivery device and a plurality of mountable elements
US9669202B2 (en) * 2009-07-07 2017-06-06 Sanofi-Aventis Deutschland Gmbh Drug delivery device and set of a drug delivery device and a plurality of mountable elements
US20120253288A1 (en) * 2009-08-27 2012-10-04 Sanofi-Aventis Deutschland Gmbh Reminder device for drug delivery devices
US20120259285A1 (en) * 2009-09-23 2012-10-11 Sanofi-Aventis Deutschland Gmbh Assembly for a drug delivery device and drug delivery device
US9402959B2 (en) * 2009-09-23 2016-08-02 Sanofi-Aventis Deutschland Gmbh Assembly for a drug delivery device and drug delivery device
US10305544B2 (en) 2009-11-04 2019-05-28 Proteus Digital Health, Inc. System for supply chain management
US9941931B2 (en) 2009-11-04 2018-04-10 Proteus Digital Health, Inc. System for supply chain management
US20130016105A1 (en) * 2009-12-02 2013-01-17 Sanofi-Aventis Deutschland Gmbh Dose display mechanism for a drug delivery device
US9463284B2 (en) * 2009-12-02 2016-10-11 Sanofi-Aventis Deutschland Gmbh Dose display mechanism for drug delivery device with first and second windows and scales
US10376218B2 (en) 2010-02-01 2019-08-13 Proteus Digital Health, Inc. Data gathering system
WO2011107568A1 (en) 2010-03-05 2011-09-09 B. Braun Melsungen Ag System and method for administering medicaments on the basis of urine values
AU2011222944B2 (en) * 2010-03-05 2013-12-19 B. Braun Melsungen Ag System and method for administering medicaments on the basis of urine values
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
US10207093B2 (en) 2010-04-07 2019-02-19 Proteus Digital Health, Inc. Miniature ingestible device
US11173290B2 (en) 2010-04-07 2021-11-16 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
WO2011126485A1 (en) * 2010-04-08 2011-10-13 Cardiac Protection Solutions, Llc Method and apparatus for delivering continuous intravenous infusion of metoprolol
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
US9554725B2 (en) * 2010-08-03 2017-01-31 Medtronic Monitoring, Inc. Medical device and methods of monitoring a patient with renal dysfunction
US20120035432A1 (en) * 2010-08-03 2012-02-09 Rodolphe Katra Medical device and methods of monitoring a patient with renal dysfunction
US10905351B2 (en) 2010-08-03 2021-02-02 Medtronic Monitoring, Inc. Medical device and methods of monitoring a patient with renal dysfunction
CN103209639A (en) * 2010-10-15 2013-07-17 费森尤斯医疗保健控股有限公司 Dry weight predictor
US10362968B2 (en) 2010-10-15 2019-07-30 Fresenius Medical Care Holdings, Inc. Bioimpedance circumference measurement
US10820827B2 (en) 2010-10-15 2020-11-03 Fresenius Medical Care Holdings, Inc. Dry weight predictor
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
US8380303B2 (en) 2011-02-25 2013-02-19 Pacesetter, Inc. Systems and methods for activating and controlling impedance-based detection systems of implantable medical devices
US9616107B2 (en) 2011-02-25 2017-04-11 Capricor Therapeutics, Inc. Therapy for kidney disease and/or heart failure
US8295918B2 (en) 2011-02-25 2012-10-23 Pacesetter, Inc. Systems and methods for activating and controlling impedance-based detection systems of implantable medical devices
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US11229378B2 (en) 2011-07-11 2022-01-25 Otsuka Pharmaceutical Co., Ltd. Communication system with enhanced partial power source and method of manufacturing same
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US9623085B2 (en) 2011-09-02 2017-04-18 Capricor Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
US8868185B2 (en) 2011-10-31 2014-10-21 Medtronic, Inc. Use of thoracic and extra-thoracic impedance for diagnostic monitoring
US9597511B2 (en) 2011-10-31 2017-03-21 Medtronic, Inc. Method to assess hemodynamic performance during cardiac resynchronization therapy optimization using admittance waveforms and derivatives
WO2013154783A1 (en) * 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
US20140031787A1 (en) * 2012-04-13 2014-01-30 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
US20130274705A1 (en) * 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
WO2013154784A1 (en) * 2012-04-13 2013-10-17 Medtronic, Inc. Feedback-based diuretic or natriuretic molecule administration
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
WO2014138796A1 (en) * 2013-03-15 2014-09-18 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US11741771B2 (en) 2013-03-15 2023-08-29 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US9764002B2 (en) 2013-03-15 2017-09-19 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10421658B2 (en) 2013-08-30 2019-09-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10498572B2 (en) 2013-09-20 2019-12-03 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10097388B2 (en) 2013-09-20 2018-10-09 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9787511B2 (en) 2013-09-20 2017-10-10 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US11102038B2 (en) 2013-09-20 2021-08-24 Otsuka Pharmaceutical Co., Ltd. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US20150127738A1 (en) * 2013-11-05 2015-05-07 Proteus Digital Health, Inc. Bio-language based communication system
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US10086138B1 (en) * 2014-01-28 2018-10-02 Masimo Corporation Autonomous drug delivery system
US11883190B2 (en) 2014-01-28 2024-01-30 Masimo Corporation Autonomous drug delivery system
US11259745B2 (en) 2014-01-28 2022-03-01 Masimo Corporation Autonomous drug delivery system
US10004754B2 (en) 2014-03-14 2018-06-26 Madeleine Pharmaceuticals Pty Ltd. ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment
US10744262B2 (en) 2015-07-19 2020-08-18 Sanmina Corporation System and method for health monitoring by an ear piece
US11666703B2 (en) 2015-07-19 2023-06-06 Trilinear Bioventures, Llc System and method for health monitoring by an ear piece
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US10368774B2 (en) 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
US11744478B2 (en) 2015-07-30 2023-09-05 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
EP3337397A4 (en) * 2015-09-25 2019-09-04 Sanmina Corporation System and method for a drug delivery and biosensor patch
WO2017054006A1 (en) 2015-09-25 2017-03-30 Sanmina Corporation System and method for a drug delivery and biosensor patch
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10797758B2 (en) 2016-07-22 2020-10-06 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10881774B2 (en) 2016-09-23 2021-01-05 Plc Medical Systems, Inc. Method and system to protect kidneys during surgery
US11793419B2 (en) 2016-10-26 2023-10-24 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
WO2019141575A1 (en) * 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Assistance in the treatment of cardiac insufficiency
US20200337590A1 (en) * 2018-01-16 2020-10-29 Bayer Aktiengesellschaft Assistance in the treatment of cardiac insufficiency
US20210236727A1 (en) * 2018-05-18 2021-08-05 Reprieve Cardiovascular, Inc. Method and system to treat acute decompensated heart failure
US11571515B2 (en) 2019-08-29 2023-02-07 Medtronic Minimed, Inc. Controlling medical device operation and features based on detected patient sleeping status
US11642078B2 (en) * 2019-12-05 2023-05-09 Medtronic, Inc. Intervention for heart failure management
US11357446B2 (en) * 2019-12-06 2022-06-14 Reprieve Cardiovascular, Inc. Managing fluid levels in a patient and associated devices, systems, and methods
US11627912B2 (en) * 2019-12-06 2023-04-18 Reprieve Cardiovascular, Inc. Managing fluid levels in a patient and associated devices, systems, and methods
US20220313158A1 (en) * 2019-12-06 2022-10-06 Reprieve Cardiovascular, Inc. Managing fluid levels in a patient and associated devices, systems, and methods
US11887712B2 (en) 2019-12-13 2024-01-30 Medtronic Minimed, Inc. Method and system for classifying detected events as labeled event combinations for processing at a client application
WO2022259115A1 (en) * 2021-06-10 2022-12-15 Terumo Kabushiki Kaisha Closed-loop home diuretic therapy system

Also Published As

Publication number Publication date
WO2009029899A1 (en) 2009-03-05
US8070742B2 (en) 2011-12-06
US20090062729A1 (en) 2009-03-05
US20090062727A1 (en) 2009-03-05
US20090062728A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
US20090062730A1 (en) Control of body fluid condition using diuretics, based on biological parameters
ES2921199T3 (en) Injection device with continuous glucose monitoring
ES2903438T3 (en) long-term medical device
EP1332440B1 (en) Data collection assembly for patient infusion system
EP2502172B1 (en) Hypoglycemic treatment systems
US20140031787A1 (en) Feedback-based diuretic or natriuretic molecule administration
US9358334B2 (en) Integrated glucose monitor and insulin injection pen with automatic emergency notification
US20130274705A1 (en) Feedback-based diuretic or natriuretic molecule administration
US20040260233A1 (en) Data collection assembly for patient infusion system
JP2008531159A (en) Device for changing the drug delivery flow rate
AU2001296588A1 (en) Data collection assembly for patient infusion system
WO2007104755A1 (en) Secure pairing of electronic devices using dual means of communication
WO2003047426A1 (en) Medication delivery device having communication capability with glucose monitor
US20180214636A1 (en) Smart Cartridge System For Containing And Releasing Medicament With Pumping Mechanism And Compressible Reservoir
EP3742449A1 (en) System and method for incorporating exercise into closed-loop diabetes therapy
US20230248907A1 (en) Infusion Unit
US20230293810A1 (en) Infusion units and related methods
EP4034204A1 (en) Drug delivery adjustment
US20050075670A1 (en) Signal device with electro-muscle stimulation feature
WO2013014470A1 (en) Method and apparatus for providing fluid
WO2017089615A1 (en) Infusion system
WO2021133440A1 (en) Connected drug delivery system for erythropoietin stimulating agents
US20230191022A1 (en) Infusion Unit
US20230113545A1 (en) Alerts in ambulatory infusion pump systems
US20230113755A1 (en) Systems and methods for delayed meal boluses in automated insulin delivery

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION